益气活血健脾化痰法调脂疗效观察及其与apoE基因多态性关系的临床研究
|
摘要
目的
1.观察益气活血、健脾化痰法指导下的调脂通脉颗粒对高脂血症气虚痰瘀证的调脂疗效。2.应用PCR-RLFP技术,研究高脂血症气虚痰瘀证人群apoE基因型与等位基因频率分布特征,并分析apoE基因多态性对研究人群脂质代谢的影响。3.在此基础上,进一步深入探究apoE基因多态性对益气活血、健脾化痰法调脂疗效的影响,以探讨遗传基因与药物疗效的关系。
方法:
检测118例高脂血症气虚痰瘀证患者apoE基因分型,按照频数计数法计算基因频率;对入组患者按随机、双盲、双模拟、阳性药物平行对照的原则,进行疗程为8周的临床试验观察,试验组64例,给予调脂通脉颗粒(太子参、茯苓、陈皮、水蛭、丹参、泽泻等),一次1袋,一日2次口服;及血脂康胶囊安慰剂,一次2粒,一日2次口服。对照组54例,给予血脂康胶囊,一次2粒,一日2次口服,及调脂通脉颗粒安慰剂,一次1袋,一日2次口服。比较观察治疗前后TC、LDL-C、TG、HDL-C、apoA1、apoB、LP(a)、AI以及中医证候的变化。观察两组部分患者治疗前后血流变学变化。
结果:
1.试验组调脂总有效率84.3%,有效降低血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、载脂蛋白B(apoB)以及动脉粥样硬化指数(AI),并且升高高密度脂蛋白胆固醇(HDL-C)(p﹤0.05),与治疗前比较差异显著;对照组调脂总有效率86.5 %,有明显降低TC、TG、LDL-C、apoB、AI,升高HDL-C作用(p﹤0.05);试验组与对照组比较,TC、TG、apoB、AI、HDL-C的变化,差异无统计学意义。在降低LDL-C方面,血脂康组优于调脂通脉颗粒组,从总体上,调脂通脉颗粒调脂疗效与血脂康相当,并且都具有良好的降低动脉粥样硬化指数作用。另外两组都能明显改善血液流变学指标,从而改善高脂血症粘、浓、聚的状态,疗效相当。治疗后试验组中医证候总积分明显低于对照组,(p﹤0.05)有显著性差异,调脂通脉颗粒改善中医证候明显优于血脂康,尤其在气虚血瘀症状方面的改善,(p﹤0.05),调脂通脉颗粒有明显优势。
2.在118例高脂血症气虚痰瘀证人群中,共检测到4种基因型,以ε3等位基因频率最高,为89.4%,其中各基因型频率分布分别是:E2/3为8.5%,E3/3为78%,E2/4为1.7%,E3/4为11.9%,apoE基因型与等位基因频率分布,与北京自然健康人群比较,差异无统计学意义。
3.apoE各基因型TC、LDL-C、apoB水平由高到低依次为E3/4﹥E3/3﹥E2/3,E3/4有明显升高TC、LDL-C、apoB的作用(p﹤0.05)。E3/4基因型HDL-C的水平在三种基因型中最低, E3/3比较,差异有统计学意义。结果还显示E3/4基因型的中医痰浊证积分明显高于E2/3、E3/3,差异有统计学意义(p﹤0.05),E3/4的气虚证候积分最高,但与E2/3、E3/3比较,差异无统计学意义。apoE基因多态性不影响TG、apoA1及LP(a)
Objective:
1.To observe the serum-lipid effect of TIAOZHI TONGMAI granule directed by method of YIQI HUOXUE HUATAN.
2.Using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to study the genotypes and allelic frequencies of QIXU TANYU syndrome population in hyperlipidemia, at the same time, analysis the effect of ApoE gene polymorphism on serum lipid.
3.Furthermore to ascertain the effect of gene polymorphism on the method of YIHUOHUOXUE JIANPIHUATAN and the relationship between gene and drug effect.
Method: The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect apoE genotype in 118 hyperlipidemia patients, according to random, double blind, double imitate and control principle, the course of treatment is 8 weeks. Experimental group has 64 patients, giving TIAOZHI TONGMAI granule, 1 big, bid, po, XUEZHIKANG placebo 2 grain, bid, po. Control group has 54 patients, giving XUEZHIKANG capsule 2 grain, bid, po, TIAOZHI TONGMAI granule placebo 1 bag, bid po. To observe the change of TC、LDL-C、TG、HDL-C、apoA1、apoB、LP(a)、AI , TCM syndrome and blood flow between pretreatment and posttreatment.
Result:
1.The total effective rate in regulating serum lipid of experimental group is 84.3%,decreacing TC、LDL-C、TG、apoB、AI, increasing HDL-C)(p﹤0.05), there are significant difference comparing to pretreatment. The total effective rate in regulating serum lipid of control group is 86.5 %, decreasing TC、TG、LDL-C、apoB、AI, increasing HDL-C)(p﹤0.05), there are no difference between experimental and control group. XUEAHIKANG group is better than TIAOZHITONGMAI granule group in lowing LDL-C. The effect on regulating serum lipid of TIAOZHITONGMAI granule is correspond to XUEZHIKANG, furthermore it can resist atherosclerosis. Tow groups can improve blood flow index, the station of increasing mocusity, thick and assemble in hyperlipidemia. TIAOZHITONGMAI granule is superior to XUEZHIKANG in improving TCM syndrome.
2.Four genotypes are found in 118 patients,ε3 is the highest accounting for 65. 6%.The frequency of E2/3,E3/3,E2/4, E3/ are 8.5%,78%,1.7%and 11.9% respectively .There are not significant difference between men and women . Compared with Beijing natural population, the genotypes and allelic frequencies
1.观察益气活血、健脾化痰法指导下的调脂通脉颗粒对高脂血症气虚痰瘀证的调脂疗效。2.应用PCR-RLFP技术,研究高脂血症气虚痰瘀证人群apoE基因型与等位基因频率分布特征,并分析apoE基因多态性对研究人群脂质代谢的影响。3.在此基础上,进一步深入探究apoE基因多态性对益气活血、健脾化痰法调脂疗效的影响,以探讨遗传基因与药物疗效的关系。
方法:
检测118例高脂血症气虚痰瘀证患者apoE基因分型,按照频数计数法计算基因频率;对入组患者按随机、双盲、双模拟、阳性药物平行对照的原则,进行疗程为8周的临床试验观察,试验组64例,给予调脂通脉颗粒(太子参、茯苓、陈皮、水蛭、丹参、泽泻等),一次1袋,一日2次口服;及血脂康胶囊安慰剂,一次2粒,一日2次口服。对照组54例,给予血脂康胶囊,一次2粒,一日2次口服,及调脂通脉颗粒安慰剂,一次1袋,一日2次口服。比较观察治疗前后TC、LDL-C、TG、HDL-C、apoA1、apoB、LP(a)、AI以及中医证候的变化。观察两组部分患者治疗前后血流变学变化。
结果:
1.试验组调脂总有效率84.3%,有效降低血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、载脂蛋白B(apoB)以及动脉粥样硬化指数(AI),并且升高高密度脂蛋白胆固醇(HDL-C)(p﹤0.05),与治疗前比较差异显著;对照组调脂总有效率86.5 %,有明显降低TC、TG、LDL-C、apoB、AI,升高HDL-C作用(p﹤0.05);试验组与对照组比较,TC、TG、apoB、AI、HDL-C的变化,差异无统计学意义。在降低LDL-C方面,血脂康组优于调脂通脉颗粒组,从总体上,调脂通脉颗粒调脂疗效与血脂康相当,并且都具有良好的降低动脉粥样硬化指数作用。另外两组都能明显改善血液流变学指标,从而改善高脂血症粘、浓、聚的状态,疗效相当。治疗后试验组中医证候总积分明显低于对照组,(p﹤0.05)有显著性差异,调脂通脉颗粒改善中医证候明显优于血脂康,尤其在气虚血瘀症状方面的改善,(p﹤0.05),调脂通脉颗粒有明显优势。
2.在118例高脂血症气虚痰瘀证人群中,共检测到4种基因型,以ε3等位基因频率最高,为89.4%,其中各基因型频率分布分别是:E2/3为8.5%,E3/3为78%,E2/4为1.7%,E3/4为11.9%,apoE基因型与等位基因频率分布,与北京自然健康人群比较,差异无统计学意义。
3.apoE各基因型TC、LDL-C、apoB水平由高到低依次为E3/4﹥E3/3﹥E2/3,E3/4有明显升高TC、LDL-C、apoB的作用(p﹤0.05)。E3/4基因型HDL-C的水平在三种基因型中最低, E3/3比较,差异有统计学意义。结果还显示E3/4基因型的中医痰浊证积分明显高于E2/3、E3/3,差异有统计学意义(p﹤0.05),E3/4的气虚证候积分最高,但与E2/3、E3/3比较,差异无统计学意义。apoE基因多态性不影响TG、apoA1及LP(a)
Objective:
1.To observe the serum-lipid effect of TIAOZHI TONGMAI granule directed by method of YIQI HUOXUE HUATAN.
2.Using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to study the genotypes and allelic frequencies of QIXU TANYU syndrome population in hyperlipidemia, at the same time, analysis the effect of ApoE gene polymorphism on serum lipid.
3.Furthermore to ascertain the effect of gene polymorphism on the method of YIHUOHUOXUE JIANPIHUATAN and the relationship between gene and drug effect.
Method: The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect apoE genotype in 118 hyperlipidemia patients, according to random, double blind, double imitate and control principle, the course of treatment is 8 weeks. Experimental group has 64 patients, giving TIAOZHI TONGMAI granule, 1 big, bid, po, XUEZHIKANG placebo 2 grain, bid, po. Control group has 54 patients, giving XUEZHIKANG capsule 2 grain, bid, po, TIAOZHI TONGMAI granule placebo 1 bag, bid po. To observe the change of TC、LDL-C、TG、HDL-C、apoA1、apoB、LP(a)、AI , TCM syndrome and blood flow between pretreatment and posttreatment.
Result:
1.The total effective rate in regulating serum lipid of experimental group is 84.3%,decreacing TC、LDL-C、TG、apoB、AI, increasing HDL-C)(p﹤0.05), there are significant difference comparing to pretreatment. The total effective rate in regulating serum lipid of control group is 86.5 %, decreasing TC、TG、LDL-C、apoB、AI, increasing HDL-C)(p﹤0.05), there are no difference between experimental and control group. XUEAHIKANG group is better than TIAOZHITONGMAI granule group in lowing LDL-C. The effect on regulating serum lipid of TIAOZHITONGMAI granule is correspond to XUEZHIKANG, furthermore it can resist atherosclerosis. Tow groups can improve blood flow index, the station of increasing mocusity, thick and assemble in hyperlipidemia. TIAOZHITONGMAI granule is superior to XUEZHIKANG in improving TCM syndrome.
2.Four genotypes are found in 118 patients,ε3 is the highest accounting for 65. 6%.The frequency of E2/3,E3/3,E2/4, E3/ are 8.5%,78%,1.7%and 11.9% respectively .There are not significant difference between men and women . Compared with Beijing natural population, the genotypes and allelic frequencies
引文
1 袁灿宇.浅谈对冠心病病因病机与辨证论治的认识.河南中医,2004,24(3):3-4.
2 关章顺,黄风起,周泽美,等.饮食组成与血脂、脂质过氧化物和冠心病关系的比较研究.心血管康复医学杂志,1999,1(18):9-12.
3 谷敬丽,石渊渊,杨瑞升.年龄性别体重指数饮食结构与血脂的关系.山西医药杂志,2005,34(7):534-536.
4 赵水平.高脂血症的病因.中国临床医生,2003,31(11):15-17.
5 周文泉.高脂血症中西医结合研究进展.中医杂志,1992,33(8):52.
6 杨瑞和.肾虚与高脂血症发病关系的探讨.中西医结合杂志,1989,9(5):33.
7 陆金宝,林水淼,曹棣芳.补肾益气方对消退兔动脉粥样硬化斑块作用的实验研究.中国老年学杂志,2002,22(5):385-387.
8 王文健.肾阳虚患者和老年人(男性)的下丘脑-垂体-性腺轴功能的初步观察.中西医结合杂志,1982,2(3):149.
9 费震宇,王文健,陈伟华,等.补肾法对实验性绝经后动脉粥样硬化作用机理的实验研究.上海中医药大学学报,2002,16(1):53-55.
10 Szafran H,Smielak Korombel W. The role of estrogens in hormonal regulation of lipid metabolism in women[J].Przegl Lek,1998,55(5):266-270.
11 Martin C,Barturen K,1VHrtinez R,et al .In vitro inhibition by estrogen of oxidative modification of human lipoproteins[J]JPhysiol Biochem,1998, 54(4):195-202.
12 Ma L,Robinson C,Thadani U,etal.Effect of 17restradiol In the rahbit :endothelium-dependent and7independent mechanisms of vascular relaxation[J].J Cardiovas Pharma,1997,30(1):130-135.
13 徐成斌. 冠心病二级预防用激素替代治疗应取慎重态度[J]. 中华内科杂志.2000,39(7):437-438.
14 叶平主编.血脂的基础与临床.北京:人民军医出版社,2002,96.
15 熊文生.从脾论治高脂血症的概况与展望.新中医,1997,(5)58-59.
16 刘 桂 荣 , 袁 汝 明 . 对 高 脂 血 其 症 几 个 问 题 的 探 讨 . 山 东 中 医 药 大 学 学报,2001,25(5):330-332.
17 张晨,赵冰,杨秀捷,等.健脾降浊方对脾虚型高脂血症大鼠脂质代谢影响的实验研究.湖北中医学院学报,2005,7(1):7-10.
18 关宝莲,齐红羽.高脂血症的中医辨证分型研究.山西中医,2005,21(1):41-42.
19 和仁.高脂血症中药治法从作用机理研究进展.云南中医杂志,1999,20(2):3l-33.
20 赵建明,赵淑媛.虚证红细胞膜流动性改变的临床研究.中国中西医结合杂志, 1996,16(6):350-351.
21 杨俐,陈学忠,尹方.高脂血症痰浊病机探讨.中医药临床杂志,2005,17(6):539-540.
22 徐济民,等.痰浊型冠心病与血脂水平关系的探讨.中西医结合杂志,1984,5:265.
23 董汉良.试谈痰瘀相关.中医杂志,1980,9:70.
24 宋剑南,刘东远,牛晓红,等.高脂血症与中医痰浊关系的实验研究关.中国中医痰浊医学杂志,1995,1(1):49-50.
25 郭宏昌,牛晓亚,张向东,等.痰浊证与血脂水平关系的研究.河南中医药学刊, 1998,13(6):18.
26 程小曲.痰浊型冠心病与血脂脂蛋白载脂蛋白的关系及痰浊证形成机理探讨.新中医,1994,(3):7.
27 能尚全,林如风,许少锋,等.冠心病中医辨证与载脂蛋白关系的初步研究.福建中医学院学报,1994,4(3):7-10.
28 韩学杰,沈绍功.冠心病心绞痛痰疲互结证的木质探讨.中国中医基础医学杂志, 2002,8(10):773-774.
29 朱红楠,马浩杰.高脂血症患者血液流变学实验观察.中国血液流变学杂志, 2001,11(3):227-227.
30 郑晓英,范建高.高脂血症对血液循环的影响.现代医药卫生,2003,19(1):17.
31 王敏,王灵,赵蜀琼.老年高脂血症患者血液流变学指标的改变.中国血液流变学杂志,2000,10(3):156-158.
32 秦任甲.血液流变学[M].北京:人民卫生出版社,1999,206-207.
33 罗尧岳,周小青,谢小兵,等.活血化瘀类方对动脉粥样硬化家兔血脂血液流变学变化的影响.湖南中医学院学报,2003,23(1):9-12.
34 俞亚琴,郭兮华.从血流变学探讨高脂血症的痰湿改变.辽宁中医志,1995,22(6):6-7.
35 袁肇凯,简亚平,黄献平,等.高脂血症痰瘀辨证的血脂和血流动力学检测分析.湖南中医学院学报,2001,21(3):1-4.
36 钱卫东,庞德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,3(11):5.
37 钱小奇.试论高脂血症的病因病机.天津中医,2002,12(19):50-52.
38 邱幸凡.络脉理论与临床[M].陕西:科学技术出版社,1991,30.
39 傅丰年,傅滨.高脂血症中西结合研究进展[J].天津中医,1995,12(6):43-44.
40 周瑕菁.中医不同治法对实验性高脂血症兔主动脉内膜脂斑形成的影响[J].中医杂志,1996,37(3):134.
41 宋剑南.从生物化学角度看痰及痰瘀相关[J].中国中西医结合杂志,2000,6(3):2.
42 陈可冀,马晓昌.关于传统血瘀证的现代分类[J].中国中西医结合杂志, 2000,20(7):487.
43 韩学杰.痰瘀同治方逆转动脉粥样硬化家兔作用机制研究.中西医结合心脑血管病杂志,2003,1(2):65.
44 赵 铎 .郑 绍 周 教 授 治 疗 高 脂 血 症 经 验 探 析 .中 国 中 医 基 础 医 学 杂 志 , 2005,11(6):372-473.
45 王敬卿,叶丽红.高脂血症、动脉粥样硬化、脑梗塞的相关性——周仲瑛老年医学学术思想探讨.中国医药学报,2004,19(11):672-674.
46 龚一萍,王幸儿.高脂血症与心脉相关性探讨北京中医药大学学报.2002,25(1):62-63.
47 张兆云,张安静,毕俊英.中医药防治高脂血症信息分析.中国中医药信息杂志, 1994,(6):33.
48 庄德成,卞善述,钱卫东.高脂血症辨证分型与血脂指标观察的相关性研究[J].江苏中医,2001,22(9):18.
49 朱学云.高脂血症中医辨证分型与血液流变学指标的相关性研究[J].湖南中医药导报,2001,7(7):355-356.
50 唐荣德,罗治华,蒋三员,等.血生化指标与高脂血症中医虚实证型的关系.中国中西医结合急救杂志,2005,12(1):5-7.
51 王亚红,赵明镜,吕希莹,等.降脂通脉方抗高脂血症及动脉粥样硬化的实验研究.北京中医药大学学报,2001,24(3):20-22.
52 刘彦珠,郭维琴,秦腊梅,等.健脾消痰化瘀法对高脂血症患者脂质氧化的影响.北京
53 沈映君等.中药药理学.人民卫生出版社.2000,868.
54 王亚红,秦建国,郭维琴,等.人参皂甙抗高脂血症及动脉粥样硬化的实验研究.中医药学刊.2006,24(3):429-430.
55 原思通.医用中药饮片学[M].北京:人民卫生出版社,2001,207-207.
56 张洪,马红斌,蔡鸿生.降脂中药浅谈[J].时珍国药研究,1995,6(1):34-34.
57 陶晋舆,吕环,张秋菊,等.泽泻抗动脉粥样硬化作用系列研究(二)[J].北京中医学院学报,1991,14(6):51.
58 李宋华,益海,生起清.现代养生保健中药辞典[M].北京:人民卫生出版社,2000,849.
59 张嘉晴,周志泳,左保华.蒲黄对高脂血症所致内皮损伤的保护作用[J].中药药理与临床,2003,19(4):20.
60 李续娥,郭宝江.决明子蛋白质和蒽醌苷对高脂血症大鼠血脂的影响.中国中药杂志, 2002,27(5):374-376.
61 李续娥,杨水云,赵文明,等.决明子蛋白质和葱酮昔对高脂血症大鼠血液流变学的影响.中草药,2002,33(5):429-431.
62 董榕.藻酸双酯钠对鹌鹑血清及动脉壁胆固醇含量的影响.中国药理与毒理学杂志, 1990,4(3):187.
63 梁诸国.中国药用海洋生物.上海:上海人民出版社.第 l 版.1977:33.
64 沈庆乐,等.山楂精降脂片对老年高脂血症干预治疗后脂蛋白(a)和一氧化氮变化的临床价值.海峡药学,2000,12(3):85-86.
65 王丽先.山楂治疗高脂血症 31 例临床观察.陕西中医学院学报,2000,23(3):34.
66 唐荣德,罗治华,蒋三员,等.高脂血症血脂和血糖及凝血因子变化的实验研究.中国医师杂志,2004,6(2):217-218.
67 丁雁, 李梅, 白晓红, 等. 中医痰瘀同源理论的实验研究. 西南国防医药, 2003,13(2):172-173.
68 王东生,袁肇凯,陈方平.养心通脉片对动脉粥样硬化大鼠痰瘀病机的影响.中国中医急症,2005,14(3):250-251.
69 张琦,江泳,陈建杉.苓桂术甘汤对高脂血症大鼠血流变学影响的实验研究.成都中医药大学学报,2003,26(3):11-14.
70 程志清,龚一萍,应华忠,等.加味金匮泽泻冲剂对实验性高脂模型的药效学研究.实用中西医结合杂志,1998,11(8):681-182.
71 白华,曲丽芳,陈洁.桂枝茯苓丸加味对实验性老龄动物高脂血症体重、体态的影响.四川生理医学杂志,2002,24(3):133-134.
72 费震宇,王文健,陈伟华,等.补肾煎对绝经后动脉粥样硬化内皮功能保护作用的实验研究.中成药,2000,24(6):6-9.
73 王亚红,姜洪茹,郭维琴,等.降脂通脉方抗动脉粥样硬化临床研究.北京中医药大学学报,2000,23(3):52-54.
74 张琦,江泳,陈建杉.苓桂术甘汤对高脂血症大鼠血流变学影响的实验研究.成都中医药大学学报,2003,26(3):11-14.
75 吴荣民,钱小奇.试论高脂血症的论治法则.2002,(1):641-642.
76 周美芳.从痰瘀论治高脂血症 88 例临床观察.贵阳中医学院学报,2005,27(1):43.
77 杨牧祥,田元祥,刘建东,等.调脂康胶囊对高脂血症患者血清 TNF 的影响.疑难病杂志,2004,3(1):4-6.
78 姚 春 . 化 痰 逐 瘀 降 脂 汤 治 疗 高 脂 血 症 的 疗 效 观 察 [J]. 辽 宁 中 医 杂 志 , 2001,28(6):350.
79 郑秋惠.益气健脾祛瘀降浊法治疗高粘高脂血症 40 例[J].河北中医 1996.18(4):9.
80 刘有泉,董选玲.益气化痰活血法治疗高脂血症124 例.陕西中医,2000,21(12):554.
81 梁晓春,郭赛珊,王香定,等.降脂中药片降脂及抗脂质过氧化损伤的临床研究及机制探讨.中国中西医结合杂志,1994,14(3):139-142.
82 汤建武,李靖.清脂五味汤与辛伐他汀治疗高血脂症的研究.现代中西医结合杂志, 2005,14(9):1132-1133.
83 张勉之,张大宁.补肾活血法治疗动脉粥样硬化56例.陕西中医, 2002,23(2):128-130.
84 张顺来.降脂汤对高脂血症和高血压临床疗效观察.天津药学,2004,16(1):44-45.
85 陈川.补肾化痰和活血对血脂代谢影响的比较[J].上海中医杂志,1997,(2):22.
86 王金荣,王知佳.降脂饮治疗高脂血症 42 例[J].辽宁中医杂志,2000,27(4):161-162.
87 徐小周,熊上中.补肾活血化痰法治疗老年高脂血症 65 例.实用中医内科杂志, 1999,13(1):18.
88 钱小奇,张敏.大柴胡汤治疗无症状性高脂血症临床研究.国医论坛,2001,16(1):11-12.
89 吴同启.从脾肝论治高脂血症 60 例.陕西中医,2004,25(2):133-134.
90 王东生,周衡,殷文学.清热利湿法调脂的临床观察.2002,8(5):50-51.
91 刘兰印,信建军.化瘀祛痰饮治疗高脂血症 70 例临床观察.四川中医,2005,23(2):56.
92 郑友丽.葛根降脂汤治疗高脂血症临床观察,上海中医药杂志,2005,39(2):14-15
93 左晋桐,张新德,李青,等.降脂 I 号治疗高脂血症 124 例疗效观察[J].新中医, 2001,33(12):20-21.
94 才向军.化浊降脂汤治疗高脂血症 80 例.陕西中医,2004,25(2):135.
95 邵明义,施斌,郑玉,等.痰瘀同治法在高脂血症治疗中的应用.河南中医, 2005,25(3):59-60.
96 肖文新.高脂血症的中医辨治浅识.时珍国医国药,2002,13(10):635.
97 雷义举.中医辨证治疗高脂血症 82 例[J].陕西中医,2002,23(6):507-508.
98 伶丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2):244.
99 杨坚毅,陈惠红.老年高脂血症的中医分型治疗[J].新中医,1996.28(8):6-8.
100 吉江文彦.柴胡加龙骨牡蛎汤对遗传性高脂血症模型家兔的作用[日].和汉医药学杂志,1998,12(5):396-397.
101 张水源.柴胡加龙骨牡蛎汤加味治疗高脂蛋白血症.福建中医杂志,1997,28(4)12-13.
102 李振明.抵挡丸治疗高脂血症 69 例.河南中医,2000,20(1):21-22.
103 阎西才,李承功,盖宝英,等.桂枝茯苓丸治疗高脂血症 39 例.山东中医杂志,1997,16(10):444-445.
104 王玉仙,马学荣.泽泻汤加味治疗高脂血症 103 例.陕西中医,2005,26(2):103-104.
105 康兴霞.茵陈五苓散加味治疗高脂血症 46 例[J].内蒙古中医药,2000,19(2):4.
106 喻嵘,王东生,周衡,等.茵陈五苓散治疗高脂蛋白血症的临床与实验研究.中国中西医结合杂志,1996,16(8):470.
107 铁萱.瓜蒌薤白半夏汤治疗高脂蛋白血症 31 例.陕西中医,1997,18(3):114.
108 薄立宏,张勇,李派.加味大黄甘草汤治疗高脂血症临床观察.河南中医药学刊. 1997,12(6):12-13.
109 韩生银.降脂灵颗粒对高脂血症血脂指标的影响.时珍国医国药,2004,15(3):133-134.
110 杨惠民,盛彤,韩丽蓓,等.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究中华中医药杂志(原中国医药学报)2005,20(4):247-248.
111 谭电波.复方调脂片治疗高脂血症98 例疗效观察.湖南中医杂志,2002,20(2):11-12.
112 郭俊,张雷,曾柱,等.复方丹参滴丸对高脂血症狗血液流变学影响的研究.中国血液流变学杂志,2004,14(1):1-5.
113 王巧云,吕欣然.复方螺旋藻胶囊对高脂血症兔血液流变学的影响.时珍国医国药, 2004,15(3):132-133.
114 曾薇,袁劲松.中西医结合治疗高脂血症45 例疗效观察.中医药导报,2005,11(2):13-14.
115 刘汉丹,张清.中西药联合降脂的临床疗效观察.四川中医,2005,23(1):46-47.
116 冯蓉.中西医结合治疗高脂血症 56 例临床观察.四川中医,2005,23(1):56-57.
117 黄维震.中西医结合治疗高脂血症 110 例.内蒙古中医药 2005,(2):20-21.
118 杨桦.中西医结合治疗高脂血症 45 例疗效观察.湖南中医杂志,2004,20(2):7-8.
119 血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究.中华心血管杂志,2005,33(2):109-115.
120 秦树存,王士雯.低密度脂蛋白受体基因多态性对血脂康调脂疗效的影响.解放军医学杂志,1999,24(4):271.
121 王晓静,曾定尹.血脂康对实验性家兔动脉粥样硬化形成及其脂质过氧化损伤的影响.中国循环杂志,1998,13(5):305-307.
122 徐伯平,程蕴琳.血脂康对低密度脂蛋白体外氧化修饰的影响.中华内科杂志, 1998,8(8):520-522.
123 李正斌,孙宗立.血脂康对高脂血症脂质过氧化作用德影响.首都医药,2000,7(3):42.
124 王曦云,盛莉.洛伐他汀治疗冠心病高胆固醇血症对血管内皮功能微循环及胰岛素敏感性的影响.中国实用内科杂志,2003,23(11):660-662.
125 陈凌, 秦永文. 血脂康胶囊治疗高胆固醇的临床效果. 药学服务与研究, 2002,2(1):39-40.
126 孙瑞华.血脂康与辛伐他汀治疗高脂血症的比较.中国药学杂志,2001,36(10):715.
127 郑英,罗希芝,王树玲,等.血脂康与辛伐他汀临床疗效的对照研究.中国药学杂志, 2001,36(10):715.
128 陆宗良,邱宗英,刘苏,等.血脂康治疗高脂血症的临床观察.中国循环杂志, 1997,12:12-15.
1 梁万年,曹红霞.心血管疾病的预防策略与干预模式.北京:心脏病学实践 2003,人民卫生出版社,3-10.
2 胡大一. 在循证医学原则指导下做好血脂异常的预防. 中国实用内科志, 2004(24)5:257-258.
3 Guo CS,Guo LZ. Molecular epidemiology and human genome project .Chin J Epidemiol,2000,21:405-40.郭存三,郭立征.分子流行病学与人类基因组计划.中华流行病学杂志,2000,21:405-406.
4 管思明,张银环,戚本玲,等.老年人血脂分布及其与疾病的关系.临床心血管杂志, 2000,16(4):167-168.
5 叶平主编.血脂的基础与临床.北京:人民军医出版社,2002:93.
6 Davign,Cohn JS,Mabil,et al.Apolipoprotein E and atherosclerosis:insight from animal and human studies[J].Clin Chim Acta,1999,286(l-2):115-143.
7 Linton MF , Atkinson JB , Fazio S .Prevention of atherosclerosis in apolipoprotein E deficentmiceby bone marrow transplantation[J]. Science, 1995,267:1034-1037.
8 Nikoulin IR, Curtiss LK. An apolipoproteinE synthetic peptide targets to lipoproteins in plasma and mediates both cellar lipoprotein interactions in vitro and acute clearance of choles terol-rich lipoproteins in viva[J].J Chin Invest,1998,101(1):223-234.
9 唐志红,夏敏,马静,等.载脂蛋白E基因敲除小鼠主动脉壁胆固醇含量的测定及意义.疾病控制杂志,2004,8(3):213-215.
10 覃丽,秦旭平,朱炳阳,等.Caveolirr 1 在载脂蛋白 E 基因敲除小鼠动脉粥样硬化形成中的变化.中国临床药理学与治疗学,2004,9(9):978-982.
11 Maor I,Aviram M.Oxidized low density lipoprotein leads to macrophage accumulation of unesterified cholesterol as a result of lysosomal trapping of the lipoprotein hydrolyzed cholesterylester[J].JLipid Res,1994, 35(5):803-819.
12 Lange Y,Steck TL .The role of intracellular cholesterol transport in cholesterol homeostasis[J].Trans Cell Biol,1996,6(6):205-208.
13 Mahley RW .Apoliprotein E:cholesterol transport protein with expanding role in cell biology[J].Science,1988,240(4852):622-630.
14 向伟,赵水平,马燕琳,等.冠心病患者外周血单核细胞载脂蛋白 E 基因表达的研究.中华心血管病杂志,2004,32(1):80.
15 向伟,马燕琳,符生苗,等.健康儿童载脂蛋白E基因表达的研究.中国自然医学杂志, 2004,6(4):212-215.
16 刘晓春,彭怀燕,覃桂芳,等.冠心病与 AOPE 基因多态性及其与血清 AopE 的关系.上海医学检验杂志,2003,18(1):36-39.
17 Laakso M .Insulin resistance and coronary heart dis easel J.Curr Onin Linidol,1996,7:217-226.
18 Rall.SC,KH Weisgraber,R W Mahley.Human apolipopro tein E .The complete amino acid sequence[J].Biol Chem,1982,257:4171-4178.
19 赵毅,沈霞.载脂蛋白 E 的性质、检测方法和临床意义.上海医学检验杂志. 1996,11(2):107-109.
20 吴红赤,谢汝娟,那士平,等.PCR-RFLP和PCR-SSCP检测技术在aopE基因多态性检测中的应用.肾脏病与透析肾移植杂志,1998,7(6):589-591.
21 Ordovas M. Cardiovascular disease genetics:A long and winding road. Curr Opin Lipidol,2003,4(1):47-54.
22 Marie-Luise Blue, W ishm as D L, Stanley Eucker, et al. Apolipoprotein E synthesis in human kidney,adrenal gland,and liver.Proc Natl Acad SciUSA,1983,80:283-287.
23 New man T C, Daw osn P A, Rude L L, et al. Quantitation ofapolipoprote in E m RNA in the liver and peripheral tissues of nonhuman primates.J Biol Chem,1985,260:2452-2457.
24 顾牛范,冯国称,江三多,等.中国汉族人群AOPE等位基因频率的初步研究.中华医学遗传学杂志,1996,13(1):8-12.
25 王秀花,高海青.载脂蛋白 E 多态性与冠心病患者脂代谢的临床研究.临床心血管病杂志,2000,16(10):440-442.
26 Davignon J, Gregg R E, Sing C F. LE apolipoprotein E polym orphis im and atherosclerosis. Arteroscleros is,1988,8:1-21.
27 黎旭,赵冬,刘静,等.北京自然人群载脂蛋白 E 基因多态性频率分布研究.首都医科大学学报,2003,24(3):268-270.
28 曾湘豫,秦斌,国汉帮,等.北京地区载脂蛋白 E 基因多态性和血清浓度的分布.中华神经科杂志,2000,33(4):237.
29 Dallongeville J,Cacan SL,Davignon J. Modulation of plasma triglyc-eride level by aopE phenotype analysis[J].J Lipid Res,1992,33:447-454.
30 Davignon J, Gregg RE,Sing CF.Apolipoprotein E polymorphism and atherosclerosis[J].Current Science,1993,5:19-21.
31 Sing CF, Davigon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation[J].AmJ HuGenet, 1985,37(2):268-285.
32 Utermann G, Pruin N, Steinmetz A, et al. Polymorphism of apolipoprotein E III effect of a single polym orphic gene locus on plasman lipid levels in man. Clin genet,1979,15(l):63.
33 沈丽华,柯开富,李作汉,等.载脂蛋白 E 基因多态性对血脂代谢的影响.现代神经疾病杂志,2002,2(6):345-347.
34 朱健华,潘闽,王惠民.载脂蛋白E基因多态性与健康人群血脂谱改变的关系.临床心血管病杂志,2002,18(2):63-65.
35 James M, Hagberg B, Kenneth RW,et al. AopE gene and gene-environment effects on plasma lipoprotein lipid levels[J].Physiol Genomics,2000,4:101-108.
36 Davignon J, Gregg RE,Sing CF.Apo E polymorphism and atherosclerosis. Atherosclerosis,1988,8:1.
37 Ruth FS, Borge G, Nordestgaarda CD,et al. Context-dependent and invariant associations between lipids,lipoproteins,and apolipoproteins and apolipoprotein E genotype[J].J Lipid Res,2000,41:1812-1822.
38 赵水平主编.临床血脂学[M].长沙:湖南科学技术出版社,1997,29-33.
39 Iausen IC,Gerdes LU, Sihm I,et al. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around theworld. Genet Epidenvol,1992,9:155-167.
40 Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis[J]. Current Science,1993,5:19-21.
41 Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyeeride levels by apoE phenotype: a meta-analysis. J Lipid Res,1992,33:447-454.
42 朱铁兵,王中林,赵水平,等.载脂蛋白 E 基因对血脂代谢的调节及其与冠心病的关系.[J].湖南医科大学学报,1998,23(2):149-151.
43 Boerwinkle E, Visvikis S, Welsh D, et al. The use of measured genotype in formation in the analysis of quantitative phenotypes in man. H.The role of apolipoprotein E polymorphism in deter mining levels, variability, and covariability of cholesterol, beta lipoprotein and triglycerides in a sample of unrelated individuals[J]. Am J Hum Genet 1987,27:567-582.
44 Ruth FS, Borge G, Nordestgaarda CD,et al. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype [J].J Lipid Res,2000,41:1812-1822.
45 Boerwinkle E, Visvikis S, Welsh D,et al. The use of measured genotype information in the analysis of quantitative phenotypes in man. H.The role of apolipoprotein E polymorphism in deter mining levels, variability, and covariability of cholesterol, beta lipoprotein and triglycerides in a sample of unrelated individuals[J].Am J Hum Genet 1987,27:567-582.
46 邹阳春,洪秀芳,胡大一,等.国人载脂蛋白 E 基因多态性与冠心病发病之间的相关性.中国动脉硬化杂志,2005,13(3):355-358.
47 Zannis VI,Just P W,Breslow JL .Human apolipooprotein E iso protein subclasses are genetically determined[J].Am J Hum Genet,1981,33(1):11-24.
48 Lehtimaki T, MoilanenT, Viikari J, et al. Apolipoprotein E geno types in Finnish youths: a cross-sectional and 6-year follow-up study[J].J Lipid Res,1990,31:487-495.
49 Lehtimaki T, MoilanenT, Viikari J, et al. Apolipoprotein E geno-types in Finnish youths: a cross-sectional and 6-year followupstudy[J].J Lipid Res,1990,31:487-495.
50 Srinivasan SR,Ehnhol m C,Elkasabany A,et al.In fluence of apolipoprotein E polymorphism on serum lipids and lipoprotein changes from childhood toadulthood The Bogalusa Heart Study[J].At he roscle rosis,1999,143:435-443.
51 Srinivasan SR,Ehnhol m C,Wattigney WA,et al.The relation of apoliprotein E polymorphism to multiple cardio rascular risk in children:the Bogalusa Heart Study[J]. Atherosclerosis,1996,123(1-2):33-42.
52 张晓,麦根荣,江钟炎.载脂蛋白E基因多态性对儿童血脂的影响.中国当代儿科杂志, 2001,3(1):11-13.
53 KaoJJ T, Sai KS, Chang CJ. The effects of AopE polymorphism on the distribution of lipids andlipoproteins in the Chinese population [J].Atherosclerosis, 1996,114(1):55-59.
54 Gerard Siest, Thierry Pillot, Anne Regis-Bailly, et al. Apolipoprotein E:An im portant gene and protein tofollow in laboratory medicine. Clin Chem,1995,41:1068-1086.
55 Margaret M Cobb, Howard Teitlebaum,Neil Risch, et al. Influence of dietary fat, apolipoprotien E plenotype and sex on plasm a lipoprotein levels. Circulation,1992,846:849.
56 Dallongevill J, Lussier-Cacans, Darignon J. Modulationof plasma triglyceride levels by apolipoprote in E phenotype: A meta-analysis. J Lipid Res,1992,33:447-454.
57 Reilly S, Ferrell R, Sing C.The genderspecific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester[J].Am J Hum Genet,1992,51:1311-1324.
58 Eto M, Sato T, Watanabe K, et al. Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoproteinE4[J].Athemsclerosis,1990,84:49-53.
59 张原力,游凯,张丽华,等.载脂蛋白 E 基因多态性对血脂及冠心病、动脉粥样硬化的影响.中华心血管病杂志,1998,26:443-447.
60 肖志杰,赵水平,聂赛,等.载脂蛋白E基因多态性对血脂的影响.中华流行病学杂志, 2005,26(7):533-536.
61 U term ann G, V ogelberg KH.SteinmetzA,etal. Polymorphism of apolipoprote in EⅡGenetics of hyperlipoprote in em is typeIII.Clin Genet, 1979,15(1):37-62.
62 王蓉,谢荣麟,黄文芳,等.载脂蛋白 E 基因多态性及其与Ⅳ型高脂血症的关系.四川医学,2005,26(4):400-401.
63 张雪梅,刘秉文,范萍,等.中国人内源性高甘油三酯血症载脂蛋白E基因多态性的研究.中华医学遗传学杂志,2001,18(2):100-104.
64 庞庆丰,王影.家族性高胆固醇血症患者载脂蛋白E基因多态性及其对血脂的可能影响.徐州医学院学报,2004,24(3):206-209.
65 张延红,窦相峰,尚蔚,等.家族性混合型高脂血症与载脂蛋白E基因多态性的研究高血压杂志,2004,12(2):127-130.
66 DSeDreS 1P. Diabetes 1995,42:1474.
67 de Man FH, de Beer F, van de laarse A, et al. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphateproteoglycan-bounlipoproteinlipase[J].Atherosclerosis,1998,136 (2):255-256.
68 Srinivasan SR, Ehnholm C,Elkasabany A, et al. Apolipoprotein E polymorphism Modulates the association between obesity and dys lipdemias during young adulthood: the bogalusa heart study[J].Metabolism,2001,50:696-702.
69 Miettinen TA, et al. Arterioscler Thormb 1994,11:1303.
70 Day I N , Wilson DI . Science , medicine and the future:genetics and cardiovascular risk. BMJ,2001,323:1409-1412.
71 De Man FH, de Beer, van de laarse A, Smelt AH, Leuven JA, Havekes LM Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphat proteoglycaer bound lipoprotein lipase. Atherosclerosi, 1998,136(2):255-262.
72 张莉莉,吕安林,王海昌,等.载脂蛋白 E 基因多态性与冠心病相关因素的关联性.心脏杂志,2004,16(3):252-254.
73 张雪梅,刘秉文.载脂蛋白 E 研究进展.中国动脉硬化杂志,2001,9(2):165-168.
74 Van EM, Van DKW, Herijgem M, et al. Essential role fox the(he patic) LDL receptor in macrophage apolipoprotein E-induction in serum cholesterol levels and atherosclerosis[J]Atherosclerosis,2001,164(1):103-112.
75 王克勤.脂蛋白与动脉粥样硬化[M].北京:人民卫生出版社,1995,151-160.
76 STENGARD JH , PEKKANEN J , EHNHOLM C , et al Genotypes with the apolipoprotein epsilon4 allele are pre2dictors of coronary heart disease mortality in a longitudinalstudy of elderly Finnishmen [J]. Hum Genet,1996,97:677-684.
77 张莉莉,吕安林,王海昌,等.载脂蛋白 E 基因多态性与冠心病相关因素的关联性.心脏杂志,2004,16(3):252-254.
78 彭健,彭澍,龚五星.不同血脂水平冠心病患者与载脂蛋白E基因多态性相关性分析.中华医学杂志,2000,80(7):516-517.
79 张莉,季彦.冠心病 42 例血浆载脂蛋白 E 基因型及脂类、内皮素、一氧化氮水平检测.南通医学院学报,2000,20(2):144-145.
80 朱铁兵,杨志键,马根山,等.冠心病患者载脂蛋白 E 基因多态性研究.中国循环杂志2000,15(4):221-222.
81 邹阳春,洪秀芳,胡大一,等.国人载脂蛋白 E 基因多态性与冠心病发病之间的相关性.中国动脉硬化杂志,2005,13(3):355-357.
82 欧阳涛,宋剑南,苗阳,等.冠心病痰瘀证与载脂蛋白 E 基因多态性关系的研究.中西医结合学报,2005,3(6):438-441.
83 李洁,张天民,李莎,等.冠心病家族史大学生 apoE 基因多态性的临床研究.国外医学·心血管疾病分册,2003,30:(4)248-250.
84 Ruth F S,Anne T H,Steffensen R,et al.Apolipoprotein E genotype:Epsilon
32 women are protected while epsilon 43 and epsilon 44 men are susceptible to ische mic heart disease .The Copenhagen city study.J Am Coll Cardiol,2000,35:1192-1199.
85 陈忠,黄峻,朱铁兵,等.早发冠心病患者同胞及子女血脂与载脂蛋白 E 基因多态性.临床心血管病杂志,2002,18(4):150-152.
86 Van Bockxmeer PM,M am otte CD. Apolipoprotein epsilon 4 hom ozygosity in young m en w ith coronary heart disease. Lancet,1992,340:879-880.
87 Cubrilo-Turek M,Stavljenic-Rukavina A, Sertic J, et al Apolipoprotein E genotypes and metabolic risk factors for coronary heart disease in middle-aged women. Coll Antropol,1998,22:149-155.
88 Scuteri A, Bos AJG, Zonderman AB, et al. Am J Med,2001,110(1):28-32.
89 朱铁兵,杨志键,马根山,等.冠心病患者载脂蛋白E基因多态性研究.中国循环杂志, 2000,15(4):221-222.
90 Sanghera DK, Ferrell RE, Aston CE, et al. Quantitative effects of the apolipoprotein E polymorphism in a biracial sample of 9-10-year-old girls[J].Arteriosclerosis,1996,126:35-42.
91 Nassar BA, Dunn J, Title LM, et al. Relation of genetic poly morphisms of apolipoprotein E , angiotensin converting enzyme apolipoprotein B-100,and glycoprotein IIa and early-onset coro nary artery heart disease[J]. Clin Biochem 1999,32:275-2825.
92 赵水平主编.临床血脂学.长沙:湖南科技出版社,1997,29.
93 金炜,陆元善,徐英华,等.载脂蛋白E基因多态性与急性心肌梗死及血胆固醇水平的关系.上海医学,1998,21(12)697-699.
94 Van Bockx mer F M,Cyril DS,Frances A, et al . Angiotensinrconverting enzyme and apolipoprotein E genotypes and restenosis after coronary an gioplasty. Circulation,1995,92:2066.
95 尹志农,李瑞杰,赵远华,等.冠心病患者AopE基因型与超敏CRP相关性探讨.国外医学临床生物化学与检验学分册,2004,25(5):387-389.
96 廖玫珍,姜宝法,徐传辉,等.ApoE 基因多态性与多因素作用致冠心病研究. 中国公共卫生,2004,20(1):55-56.
97 Chin B,Viira E, Tucker W,et al. Chlamydia pneumoniae,cytomegalovirus and herpes simplex virus in atherosclerosis of the carotid artery[J].Circu lation,1997,96:2144-2148.
98 陈谦,周新,刘芳,等.冠心病患者 apoE 基因调控序列-219( QT)多态性及与血脂的关系基础医学与临床,2002,22(2):121-124.
99 liveskoski E, Perola M, Lehtimaki T. Age-dependent association of Apolioprotein E genotype with coronary and aortic atheroscle rosis in middleaged men an autopsy study[J] .Circulation,1999,100:608-613.
100 白小涓,赵玫,王勃,等.心肌梗死患者及同胞血脂异常AOPE基因多态性分析.中华医学杂志,2001,81(6):340-343.
101 Chambless LE, Folsom AR, Clegg LX, et al . Carotid wall thickness is predic live of incident clinical stroke,the atherosclerosis risk in communiti(ARIC) study.Am J Epidemol,2000,161(5):478-487.
102 陈忠,黄峻,朱铁兵,等.早发冠心病患者颈总动脉内膜-中层厚度与载脂蛋白E基因型的关系.中国动脉硬化杂志,2002,10(5):434-436.
103 谢月娥,田应中,伍有权,等.不同剂量茶色素治疗高脂血症疗效比较.中国现代医学杂志,2000,10(5):81.
104 尚延忠,叶平,丁小平.载脂蛋自 E 基因多态性对调脂疗效的影响[J].中华老年心脑血管病杂志,2001,3(4):230-232.
105 Carmena R, Roederer G, Nbilloux H, LussierCacan S, Davignon J. The re sponse to lovastatin treatment in patiens with heterozygous familial hypercholester olemia is modulated apolipoproteinE polymorphism. Ivhtaboh'sm,1993,42(7):895-901.
106 张加芳,杨玖玲,张真路,等.载脂蛋白 E 基因多态性与尼尔雌醇的调脂作用.中华老年医学杂志,2002,21(5):329-312.
107 李旭平,周胜华,赵水平,等.载脂蛋白 E 的基因型对降脂治疗反应性的影响.中国现代医学杂志,2002,12(17):81-82.
108 Gerdes LU,Gerdes C,Kervinen K, et al . The apolipoprotein E ep silon 4 allele determines prognosis and the effect on prognosis of sim vastatin in survivors of myocar al infarction:a substudy of the Scandinanvian simvastatin survival study Circulation,2000,101(12) :1366-1371.
109 Takemoto M,Liao JK. Pleiotropic effect of 3-Hydroxy-3-Methylg lutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vase Bio1,2001,21:1712-1719.
110 张莉莉,吕安林,贾国良,等.载脂蛋白E基因多态性对他汀类药物调脂消斑的影响.第四军医大学学报,2004,25(11):1029-1031.
111 Allantyne CM, Herd JA, Stein EA, et al. Apolipoprotein E genotypes and response of plasma lipids and progression7regression of coronary atherosclerosis to lipid7lowering drug therapy[J]J Am Coll Cardiol,2000,36(5):1572-1578.
112 Pedro-Botet J,Schaefer EJ, Bakker Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner[J].Atherosclerosis,2001,158(1):183-193.
113 赵水平.他汀类药物降脂疗效个体差异及其机制.中南药学,2003,1(4):195-196.
114 Eto M, Sato T, Watanabe K, Iwashima Y, Nbkino I . Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with andwithout apolipoprotein E4. Atherosclerosis,1990,84(1):49-53.
115 Nettinen TA,Gylling H, Uanhanen H. Serum cholesterol response to dietary cholesterol and apoprotein E phenotype . Lancet,1988,1:1261.
116 Erkkila AT, Sarkkinen ES, Lindi V, Lehto S, Laakso M, Uusitupa MI. ApoE polymorphism and the hype rtriglyceride mic effect of dietary sucrose . Am J Cfn Nutr,2001,73(4):746-752.
117 Lehtimaki T, FmnkbergLakkala H, Solakivi T, Koivisto AM, Laippala P, Ehur hot m C, et al . The effect of shon-term fasting,apolipoproteinEgene polymor phism, and sex on plasma lipids. Am」Cfn Nutr,1997,6(3):599-605.
118 汪春红,周新,周光娣,等.冠心病易感基因载脂蛋白 E、低密度脂蛋白受体多态性与烟、酒的交互作用的研究.中华医学杂志,2004,84(7):554-558.
119 Fickl H,Van Antwerpen VL,Richards GA, et al. Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers.Athersclerosis,1996,124:75-81.
120 Smith JD, Miyata M , Poulin SE , et al. The relationship between apolipoprptein E and serum oxidation7related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res,1998,28:116-121.
121 Taimela S, Ehtimaki T, Kimmo VK. et al. The effect of physical activity on serum total and low-density lipoprotein cholesterol concentration varies with apolipoprotein E phenotype in male children and young adults. The cardiovascular Risk in Young Finns Study[J].Metabolism,1996,45(7):797-803.
1. 赵水平主编.临床血脂学.长沙:湖南科学技术出版社,1997,32.
1 叶任高主编.内科学[M].第五版.人民卫生出版社,2000,830.
2 郭宏昌,牛晓亚,张向东,等.痰浊证与血脂水平关系的研究.河南中医药学刊, 1998.13(6):18.
3 宋剑南.从生物化学角度看痰及痰瘀相关[J].中国中西医结合杂志,2000,6(3):42.
4 俞亚琴, 郭兮华. 从血流变学探讨高脂血症的痰湿改变. 辽宁中医杂志, 1995,22(6):6-7.
5 陈可冀,马晓昌.关于传统血瘀证的现代分类[J].中国中西医结合杂志, 2000,20(7):487.
6 王剑,严灿,吴丽丽,等.无形之痰实质假想.中国中医基础医学杂志, 1999,(10):44-46.
7 王东生,袁肇凯,陈方平.动脉粥样硬化与痰瘀病理.成都中医药大学学报, 2003,26(4):57-58.
8 宋剑南,刘东远,牛晓红,等.高脂血症与中医痰浊关系的实验研究.中国中医基础医学杂志,1995,1(1):49-51.
9 熊文生.从脾论治高脂血症的概况与展望.新中医,1997,(5)58-59.
10 赵建明,赵淑媛.脾虚证红细胞膜流动性改变的临床研究.中国中西医结合杂志, 1996,16(6):350-351.
11 史大卓,马晓昌,高修安.活血化瘀方药防治动脉粥样硬化概况[J].中医杂志,1995,36(1):434.
12 刘光艳,孙文静.益气活血Ⅱ号方药对家兔实验性高脂血症的影响.辽宁药物与临床, 2004,7(1):15-16.
13 王亚红,姜洪茹,郭维琴,等.降脂通脉方抗动脉粥样硬化临床研究.北京中医药大学学报,2000,23(3):52-54.
14 杨惠民,盛彤,韩丽蓓,等.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究.中华中医药杂志(原中国医药学报),2005,20(4):247-248.
15 雷载权主编.中药学.上海:上海科学技术出版社,1995,154.
16 刘雪利.陈皮果胶对家兔实验性动脉周样硬化的形态学影响.现代应用药学, 1992,9(3):106.
17 陈丽娜, 朱晓新. 丹参改善血液流变性的实验研究进展.中国中药杂志,2005,30(8):630-635.
18 严常开,刘惟莞,敖英,等.丹参素胶囊活血化瘀作用的实验研究.中成药, 2003,25(8):637.
19 水蛭泻浊汤治疗高脂血症 48 例临床观察[J].吉林中医药,2002,(4):12.
20 秦百宜,许素贞,钱彦丛,等.水蛭对血清胆固醇、血液粘度及血栓形成的影响.中药材,1994,17(10):33-35.
21 陶晋舆,吕环,张秋菊,等.泽泻抗动脉粥样硬化作用系列研究(二)[J].北京中医学院学报,1991,14(6):51.
22 李续娥,杨水云,赵文明,等.决明子蛋白质和蒽醌苷对高脂血症大鼠血液流变学的影响.中草药,2002,33(5):429-431.
23 毛峻琴,宓鹤鸣.大豆异黄酮的研究进展.中草药,2000,31(1):61-64.
24 胡大一.在循证医学原则指导下做好血脂异常的预防.中国实用内科杂志,2004(24)5:257-258
25 徐成斌.血脂异常的药物治疗新进展.中华心血管病杂志,2001,29:189-192.
26 马丽媛,傅继第.载脂蛋白 B 基因多态性分析及其临床意义[J].高血压杂志, 1999,7(3):201.
27 Mackness ML,Durrington PN,Mackness B .How high-de nsity lipoproteins against the effects oflipidperoxidation.CurrOpin Lipidol ,2000,11:383-388.
28 李友元.自由基反应与肝损伤[J].国外医学·生理病理科学与临床分册, 1991,11(3):13
29 黄春林.降脂中药的探索.广东医学,1984,(50):21.
30 孙锡铭,蔡江海,王南,等.用两性霉素 B-细胞模型法筛选胆固醇内源性合成抑制剂.中西医结合杂志,1989,9(10):604.
31 周文泉,方醉,周鸿.高脂血症中西医结合研究进展.中医杂志,1992,33(8):52.
32 刘春堂,胡文豪.痰瘀同治降血脂 36 例.四川中医,1986,4(9):43.
33 刘君莉.水蛭粉治疗高脂血症 25 例.新中医,1985,17(2):36.
34 屈柏松,李家庚.实用中医心血管病学.第 1 版,北京:科学技术文献出版社, 1993,294-300.
35 赵春亭,赵子文主编.临床血液流变学.第 1 版.北京:人民卫生出版社,1997.
36 王敏,王灵,赵蜀琼.老年高脂血症患者血液流变学指标的改变.中国血液流变学杂志,2000,10(3):157.
37 刘晓颖,李凤文,张立石,等.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响[J].中国中医基础医学杂志,1998,4(3):15-17.
38 Gotto AM,Whitney E,Stein EA, et al. Relation between base line and on treatment lipid parameters and first acute major coro nary events in the air force/texas coronary atherosclerosis preven tion study Circulation,2000,101:477-484.
39 Manninen V, Tenkanen L,Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study implications for treatment. Circulation,1992,85:37-45.
40 Assmann G. Lipid Metabolism Disorders and.CHD MMV Medizin Verlag,1993,16:41-43.
41 Ass mann G,Cullen P,Schulte H. The Munster heart study (PROCAM) resultsof follow-up at 8 years. Eur Heart J,1998,19(suppl):A2-A11.
42 de Andrade M, Thandi I,Brown S,et al . Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis[J].Am J Hum Genet,1995,56:379-390.
43 Evans AE. Hum Genet, 1993,92(2):101-107.
44 王晔,郑惠民.载脂蛋白 E 与脑血管病.国外医学脑血管疾病分册,2000,8:139-141.
45 Zaman MM, Ikemoto S, Yoshiike N, et al. Association of apolipopro tein genetic polymorphism with plasma cholesterol in a Japanese ru ral population: the Shibata Study. Arterioscler Thromb Vasc Biol,1997,17:3495-350.
46 Pablos-mendez A, Mayeux R, Ngai C, et al. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioseler Thromb Vase Biol,1997,17:3534-3541.
47 Hixson JE. Arteriosder Tluomb Vase Biol,1991,11(5):1237-1244.
48 李伟,管思明,戚本玲,等.老年冠心病患者载脂蛋白 E 基因多态性检测的临床意义.中华老年医学杂志.2003,22(9):214-217.
49 周娟,朱健华,沈丽华等.冠心病及脑梗塞患者载脂蛋白E基因多态性研究.中国误诊学杂志,2004,4(1):19-21.
50 张原力,游凯,张丽华,等.载脂蛋白 E 基因多态性对血脂及冠心病、动脉粥样硬化的影响.中华心血管病杂志,1998,26:443-447.
51 王秀花,高海青.载脂蛋白 E 多态性与冠心病患者脂代谢的临床研究.临床心血管病杂志,2000,16(10):440-442.
52 刘华欣,曹丽春,周涌,等.不同人群载脂蛋白 E 基因多态性分布状态的研究.中国医师杂志,2000,2(9):530-532.
53 Sing CF, Davigon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation [J].Am J Hum Genet, 1985,37(2):268-285.
54 Lin SK, Kao JT, Tsai SM, Tsai LY, Lin Mr,Lai CJ, et al. Association of apolipoprotein E genotypes with serum lipid profiles in a healthy population of Tai wan. Ann Qin Lab Sci,2004,34(4):443-448.
55 Loparev V N,Cartas M A,Monken C E,et al.An effi cient and simple method of DNA extraction from whole blood and cell line to identify infection agents .J VirolMethods,1990,34(1):105-109.
56 Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis[J]. Current Science,1993,5:11-21.
57 de Andrade M, Thandi I,Brown S,et al . Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis[J].Am J Hum Genet,1995,56:379-390.
58 袁如玉,梁爽霖,毛用敏,等.载脂蛋白E等位基因多态性与冠心病相关性的研究[J].中国心血管病杂志,1998,3:320-322.
59 Pablos-mendez A, Mayeux R, Ngai C, et al. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly pop elation. Arterioseler Thromb Vase Biol, 1997,17:3534-3541.
60 Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyeeride levels by apoE phenotype:a meta-analysis. J Lipid Res,1992,33:447-454.
61 Zhao SP et al.Arteioscler Thromb,1993,13:316-323.
62 Eggertesen G,Tegel man K,Ericsson S,et al. Apolipoprotein polymorphism in a healthy Swedish popula-tion:Variation of allele frequency with age and relation to serum lipid concentration .Clin Chem1993,39:2525-2525.
63 Pablos Mendez A,Richard M,Colleen N,et al.Associa tion of apoE polymorphism with plasma lipid levels in a multiethinic elderly population .Arterioscler Thromb Vase Bi of 1997,17:3534-3541.
64 Naoumova RP, Marais AD, Mountney J, et al. Plasma meva Ionic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMGCoA reductase inhibitorsinfamilialbypercholesterolaem[J].Atheroscleroszs,1996,119(2):
203.
65 Wilson PW, Schaefer EJ, Larson MG, et al. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioseler Tbromb Vase Biol, 1996,16:1250-1255.
66 Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet, 1985, 37:268-285.
67 袁肇凯,简亚平,黄献平,等.高脂血症痰瘀辨证的血脂和血流动力学检测分析.湖南中医学院学报,2001,21(3):1-4.
68 李旭平,周胜华,赵水平,等.载脂蛋白 E 的基因型对降脂治疗反应性的影响.中国现代医学杂志,2002,12(17):81-82.
69 Carmena R, Roederer G, Nbilloux H, LussierCacan S, Davignon J. The response to lovastatin treatment in patiens with heterozygous familial hypercholesterolemia is modulated by apolipoproteinE polymorphism. Metabolism, 1993,42(7):895-901.
70 O' Nblley JP, Illingworth DR. The affluence of apo;ipoproteinE phenotype on the response to lovastatin therapy in patients with heteroaygous familial 场 perchol esterolemia. AItaboh'sm, 1990,39(2):150-154.
71 Sandllehy C, Casals E, Rodriguez cellar C, Zambon D,qnet J, Ballesta AM, et al . Lack of interaction of apolipoproteinE phenotype with the lipoproteinrespouse to lovastatin or gemfibrozil in patients with primary 场percholesterole mia Ivktabolism, 1998,47(5):560-565.
2 关章顺,黄风起,周泽美,等.饮食组成与血脂、脂质过氧化物和冠心病关系的比较研究.心血管康复医学杂志,1999,1(18):9-12.
3 谷敬丽,石渊渊,杨瑞升.年龄性别体重指数饮食结构与血脂的关系.山西医药杂志,2005,34(7):534-536.
4 赵水平.高脂血症的病因.中国临床医生,2003,31(11):15-17.
5 周文泉.高脂血症中西医结合研究进展.中医杂志,1992,33(8):52.
6 杨瑞和.肾虚与高脂血症发病关系的探讨.中西医结合杂志,1989,9(5):33.
7 陆金宝,林水淼,曹棣芳.补肾益气方对消退兔动脉粥样硬化斑块作用的实验研究.中国老年学杂志,2002,22(5):385-387.
8 王文健.肾阳虚患者和老年人(男性)的下丘脑-垂体-性腺轴功能的初步观察.中西医结合杂志,1982,2(3):149.
9 费震宇,王文健,陈伟华,等.补肾法对实验性绝经后动脉粥样硬化作用机理的实验研究.上海中医药大学学报,2002,16(1):53-55.
10 Szafran H,Smielak Korombel W. The role of estrogens in hormonal regulation of lipid metabolism in women[J].Przegl Lek,1998,55(5):266-270.
11 Martin C,Barturen K,1VHrtinez R,et al .In vitro inhibition by estrogen of oxidative modification of human lipoproteins[J]JPhysiol Biochem,1998, 54(4):195-202.
12 Ma L,Robinson C,Thadani U,etal.Effect of 17restradiol In the rahbit :endothelium-dependent and7independent mechanisms of vascular relaxation[J].J Cardiovas Pharma,1997,30(1):130-135.
13 徐成斌. 冠心病二级预防用激素替代治疗应取慎重态度[J]. 中华内科杂志.2000,39(7):437-438.
14 叶平主编.血脂的基础与临床.北京:人民军医出版社,2002,96.
15 熊文生.从脾论治高脂血症的概况与展望.新中医,1997,(5)58-59.
16 刘 桂 荣 , 袁 汝 明 . 对 高 脂 血 其 症 几 个 问 题 的 探 讨 . 山 东 中 医 药 大 学 学报,2001,25(5):330-332.
17 张晨,赵冰,杨秀捷,等.健脾降浊方对脾虚型高脂血症大鼠脂质代谢影响的实验研究.湖北中医学院学报,2005,7(1):7-10.
18 关宝莲,齐红羽.高脂血症的中医辨证分型研究.山西中医,2005,21(1):41-42.
19 和仁.高脂血症中药治法从作用机理研究进展.云南中医杂志,1999,20(2):3l-33.
20 赵建明,赵淑媛.虚证红细胞膜流动性改变的临床研究.中国中西医结合杂志, 1996,16(6):350-351.
21 杨俐,陈学忠,尹方.高脂血症痰浊病机探讨.中医药临床杂志,2005,17(6):539-540.
22 徐济民,等.痰浊型冠心病与血脂水平关系的探讨.中西医结合杂志,1984,5:265.
23 董汉良.试谈痰瘀相关.中医杂志,1980,9:70.
24 宋剑南,刘东远,牛晓红,等.高脂血症与中医痰浊关系的实验研究关.中国中医痰浊医学杂志,1995,1(1):49-50.
25 郭宏昌,牛晓亚,张向东,等.痰浊证与血脂水平关系的研究.河南中医药学刊, 1998,13(6):18.
26 程小曲.痰浊型冠心病与血脂脂蛋白载脂蛋白的关系及痰浊证形成机理探讨.新中医,1994,(3):7.
27 能尚全,林如风,许少锋,等.冠心病中医辨证与载脂蛋白关系的初步研究.福建中医学院学报,1994,4(3):7-10.
28 韩学杰,沈绍功.冠心病心绞痛痰疲互结证的木质探讨.中国中医基础医学杂志, 2002,8(10):773-774.
29 朱红楠,马浩杰.高脂血症患者血液流变学实验观察.中国血液流变学杂志, 2001,11(3):227-227.
30 郑晓英,范建高.高脂血症对血液循环的影响.现代医药卫生,2003,19(1):17.
31 王敏,王灵,赵蜀琼.老年高脂血症患者血液流变学指标的改变.中国血液流变学杂志,2000,10(3):156-158.
32 秦任甲.血液流变学[M].北京:人民卫生出版社,1999,206-207.
33 罗尧岳,周小青,谢小兵,等.活血化瘀类方对动脉粥样硬化家兔血脂血液流变学变化的影响.湖南中医学院学报,2003,23(1):9-12.
34 俞亚琴,郭兮华.从血流变学探讨高脂血症的痰湿改变.辽宁中医志,1995,22(6):6-7.
35 袁肇凯,简亚平,黄献平,等.高脂血症痰瘀辨证的血脂和血流动力学检测分析.湖南中医学院学报,2001,21(3):1-4.
36 钱卫东,庞德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,3(11):5.
37 钱小奇.试论高脂血症的病因病机.天津中医,2002,12(19):50-52.
38 邱幸凡.络脉理论与临床[M].陕西:科学技术出版社,1991,30.
39 傅丰年,傅滨.高脂血症中西结合研究进展[J].天津中医,1995,12(6):43-44.
40 周瑕菁.中医不同治法对实验性高脂血症兔主动脉内膜脂斑形成的影响[J].中医杂志,1996,37(3):134.
41 宋剑南.从生物化学角度看痰及痰瘀相关[J].中国中西医结合杂志,2000,6(3):2.
42 陈可冀,马晓昌.关于传统血瘀证的现代分类[J].中国中西医结合杂志, 2000,20(7):487.
43 韩学杰.痰瘀同治方逆转动脉粥样硬化家兔作用机制研究.中西医结合心脑血管病杂志,2003,1(2):65.
44 赵 铎 .郑 绍 周 教 授 治 疗 高 脂 血 症 经 验 探 析 .中 国 中 医 基 础 医 学 杂 志 , 2005,11(6):372-473.
45 王敬卿,叶丽红.高脂血症、动脉粥样硬化、脑梗塞的相关性——周仲瑛老年医学学术思想探讨.中国医药学报,2004,19(11):672-674.
46 龚一萍,王幸儿.高脂血症与心脉相关性探讨北京中医药大学学报.2002,25(1):62-63.
47 张兆云,张安静,毕俊英.中医药防治高脂血症信息分析.中国中医药信息杂志, 1994,(6):33.
48 庄德成,卞善述,钱卫东.高脂血症辨证分型与血脂指标观察的相关性研究[J].江苏中医,2001,22(9):18.
49 朱学云.高脂血症中医辨证分型与血液流变学指标的相关性研究[J].湖南中医药导报,2001,7(7):355-356.
50 唐荣德,罗治华,蒋三员,等.血生化指标与高脂血症中医虚实证型的关系.中国中西医结合急救杂志,2005,12(1):5-7.
51 王亚红,赵明镜,吕希莹,等.降脂通脉方抗高脂血症及动脉粥样硬化的实验研究.北京中医药大学学报,2001,24(3):20-22.
52 刘彦珠,郭维琴,秦腊梅,等.健脾消痰化瘀法对高脂血症患者脂质氧化的影响.北京
53 沈映君等.中药药理学.人民卫生出版社.2000,868.
54 王亚红,秦建国,郭维琴,等.人参皂甙抗高脂血症及动脉粥样硬化的实验研究.中医药学刊.2006,24(3):429-430.
55 原思通.医用中药饮片学[M].北京:人民卫生出版社,2001,207-207.
56 张洪,马红斌,蔡鸿生.降脂中药浅谈[J].时珍国药研究,1995,6(1):34-34.
57 陶晋舆,吕环,张秋菊,等.泽泻抗动脉粥样硬化作用系列研究(二)[J].北京中医学院学报,1991,14(6):51.
58 李宋华,益海,生起清.现代养生保健中药辞典[M].北京:人民卫生出版社,2000,849.
59 张嘉晴,周志泳,左保华.蒲黄对高脂血症所致内皮损伤的保护作用[J].中药药理与临床,2003,19(4):20.
60 李续娥,郭宝江.决明子蛋白质和蒽醌苷对高脂血症大鼠血脂的影响.中国中药杂志, 2002,27(5):374-376.
61 李续娥,杨水云,赵文明,等.决明子蛋白质和葱酮昔对高脂血症大鼠血液流变学的影响.中草药,2002,33(5):429-431.
62 董榕.藻酸双酯钠对鹌鹑血清及动脉壁胆固醇含量的影响.中国药理与毒理学杂志, 1990,4(3):187.
63 梁诸国.中国药用海洋生物.上海:上海人民出版社.第 l 版.1977:33.
64 沈庆乐,等.山楂精降脂片对老年高脂血症干预治疗后脂蛋白(a)和一氧化氮变化的临床价值.海峡药学,2000,12(3):85-86.
65 王丽先.山楂治疗高脂血症 31 例临床观察.陕西中医学院学报,2000,23(3):34.
66 唐荣德,罗治华,蒋三员,等.高脂血症血脂和血糖及凝血因子变化的实验研究.中国医师杂志,2004,6(2):217-218.
67 丁雁, 李梅, 白晓红, 等. 中医痰瘀同源理论的实验研究. 西南国防医药, 2003,13(2):172-173.
68 王东生,袁肇凯,陈方平.养心通脉片对动脉粥样硬化大鼠痰瘀病机的影响.中国中医急症,2005,14(3):250-251.
69 张琦,江泳,陈建杉.苓桂术甘汤对高脂血症大鼠血流变学影响的实验研究.成都中医药大学学报,2003,26(3):11-14.
70 程志清,龚一萍,应华忠,等.加味金匮泽泻冲剂对实验性高脂模型的药效学研究.实用中西医结合杂志,1998,11(8):681-182.
71 白华,曲丽芳,陈洁.桂枝茯苓丸加味对实验性老龄动物高脂血症体重、体态的影响.四川生理医学杂志,2002,24(3):133-134.
72 费震宇,王文健,陈伟华,等.补肾煎对绝经后动脉粥样硬化内皮功能保护作用的实验研究.中成药,2000,24(6):6-9.
73 王亚红,姜洪茹,郭维琴,等.降脂通脉方抗动脉粥样硬化临床研究.北京中医药大学学报,2000,23(3):52-54.
74 张琦,江泳,陈建杉.苓桂术甘汤对高脂血症大鼠血流变学影响的实验研究.成都中医药大学学报,2003,26(3):11-14.
75 吴荣民,钱小奇.试论高脂血症的论治法则.2002,(1):641-642.
76 周美芳.从痰瘀论治高脂血症 88 例临床观察.贵阳中医学院学报,2005,27(1):43.
77 杨牧祥,田元祥,刘建东,等.调脂康胶囊对高脂血症患者血清 TNF 的影响.疑难病杂志,2004,3(1):4-6.
78 姚 春 . 化 痰 逐 瘀 降 脂 汤 治 疗 高 脂 血 症 的 疗 效 观 察 [J]. 辽 宁 中 医 杂 志 , 2001,28(6):350.
79 郑秋惠.益气健脾祛瘀降浊法治疗高粘高脂血症 40 例[J].河北中医 1996.18(4):9.
80 刘有泉,董选玲.益气化痰活血法治疗高脂血症124 例.陕西中医,2000,21(12):554.
81 梁晓春,郭赛珊,王香定,等.降脂中药片降脂及抗脂质过氧化损伤的临床研究及机制探讨.中国中西医结合杂志,1994,14(3):139-142.
82 汤建武,李靖.清脂五味汤与辛伐他汀治疗高血脂症的研究.现代中西医结合杂志, 2005,14(9):1132-1133.
83 张勉之,张大宁.补肾活血法治疗动脉粥样硬化56例.陕西中医, 2002,23(2):128-130.
84 张顺来.降脂汤对高脂血症和高血压临床疗效观察.天津药学,2004,16(1):44-45.
85 陈川.补肾化痰和活血对血脂代谢影响的比较[J].上海中医杂志,1997,(2):22.
86 王金荣,王知佳.降脂饮治疗高脂血症 42 例[J].辽宁中医杂志,2000,27(4):161-162.
87 徐小周,熊上中.补肾活血化痰法治疗老年高脂血症 65 例.实用中医内科杂志, 1999,13(1):18.
88 钱小奇,张敏.大柴胡汤治疗无症状性高脂血症临床研究.国医论坛,2001,16(1):11-12.
89 吴同启.从脾肝论治高脂血症 60 例.陕西中医,2004,25(2):133-134.
90 王东生,周衡,殷文学.清热利湿法调脂的临床观察.2002,8(5):50-51.
91 刘兰印,信建军.化瘀祛痰饮治疗高脂血症 70 例临床观察.四川中医,2005,23(2):56.
92 郑友丽.葛根降脂汤治疗高脂血症临床观察,上海中医药杂志,2005,39(2):14-15
93 左晋桐,张新德,李青,等.降脂 I 号治疗高脂血症 124 例疗效观察[J].新中医, 2001,33(12):20-21.
94 才向军.化浊降脂汤治疗高脂血症 80 例.陕西中医,2004,25(2):135.
95 邵明义,施斌,郑玉,等.痰瘀同治法在高脂血症治疗中的应用.河南中医, 2005,25(3):59-60.
96 肖文新.高脂血症的中医辨治浅识.时珍国医国药,2002,13(10):635.
97 雷义举.中医辨证治疗高脂血症 82 例[J].陕西中医,2002,23(6):507-508.
98 伶丽娟.高脂血症的病因病机及辨证分型治疗[J].中医药学刊,2002,20(2):244.
99 杨坚毅,陈惠红.老年高脂血症的中医分型治疗[J].新中医,1996.28(8):6-8.
100 吉江文彦.柴胡加龙骨牡蛎汤对遗传性高脂血症模型家兔的作用[日].和汉医药学杂志,1998,12(5):396-397.
101 张水源.柴胡加龙骨牡蛎汤加味治疗高脂蛋白血症.福建中医杂志,1997,28(4)12-13.
102 李振明.抵挡丸治疗高脂血症 69 例.河南中医,2000,20(1):21-22.
103 阎西才,李承功,盖宝英,等.桂枝茯苓丸治疗高脂血症 39 例.山东中医杂志,1997,16(10):444-445.
104 王玉仙,马学荣.泽泻汤加味治疗高脂血症 103 例.陕西中医,2005,26(2):103-104.
105 康兴霞.茵陈五苓散加味治疗高脂血症 46 例[J].内蒙古中医药,2000,19(2):4.
106 喻嵘,王东生,周衡,等.茵陈五苓散治疗高脂蛋白血症的临床与实验研究.中国中西医结合杂志,1996,16(8):470.
107 铁萱.瓜蒌薤白半夏汤治疗高脂蛋白血症 31 例.陕西中医,1997,18(3):114.
108 薄立宏,张勇,李派.加味大黄甘草汤治疗高脂血症临床观察.河南中医药学刊. 1997,12(6):12-13.
109 韩生银.降脂灵颗粒对高脂血症血脂指标的影响.时珍国医国药,2004,15(3):133-134.
110 杨惠民,盛彤,韩丽蓓,等.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究中华中医药杂志(原中国医药学报)2005,20(4):247-248.
111 谭电波.复方调脂片治疗高脂血症98 例疗效观察.湖南中医杂志,2002,20(2):11-12.
112 郭俊,张雷,曾柱,等.复方丹参滴丸对高脂血症狗血液流变学影响的研究.中国血液流变学杂志,2004,14(1):1-5.
113 王巧云,吕欣然.复方螺旋藻胶囊对高脂血症兔血液流变学的影响.时珍国医国药, 2004,15(3):132-133.
114 曾薇,袁劲松.中西医结合治疗高脂血症45 例疗效观察.中医药导报,2005,11(2):13-14.
115 刘汉丹,张清.中西药联合降脂的临床疗效观察.四川中医,2005,23(1):46-47.
116 冯蓉.中西医结合治疗高脂血症 56 例临床观察.四川中医,2005,23(1):56-57.
117 黄维震.中西医结合治疗高脂血症 110 例.内蒙古中医药 2005,(2):20-21.
118 杨桦.中西医结合治疗高脂血症 45 例疗效观察.湖南中医杂志,2004,20(2):7-8.
119 血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究.中华心血管杂志,2005,33(2):109-115.
120 秦树存,王士雯.低密度脂蛋白受体基因多态性对血脂康调脂疗效的影响.解放军医学杂志,1999,24(4):271.
121 王晓静,曾定尹.血脂康对实验性家兔动脉粥样硬化形成及其脂质过氧化损伤的影响.中国循环杂志,1998,13(5):305-307.
122 徐伯平,程蕴琳.血脂康对低密度脂蛋白体外氧化修饰的影响.中华内科杂志, 1998,8(8):520-522.
123 李正斌,孙宗立.血脂康对高脂血症脂质过氧化作用德影响.首都医药,2000,7(3):42.
124 王曦云,盛莉.洛伐他汀治疗冠心病高胆固醇血症对血管内皮功能微循环及胰岛素敏感性的影响.中国实用内科杂志,2003,23(11):660-662.
125 陈凌, 秦永文. 血脂康胶囊治疗高胆固醇的临床效果. 药学服务与研究, 2002,2(1):39-40.
126 孙瑞华.血脂康与辛伐他汀治疗高脂血症的比较.中国药学杂志,2001,36(10):715.
127 郑英,罗希芝,王树玲,等.血脂康与辛伐他汀临床疗效的对照研究.中国药学杂志, 2001,36(10):715.
128 陆宗良,邱宗英,刘苏,等.血脂康治疗高脂血症的临床观察.中国循环杂志, 1997,12:12-15.
1 梁万年,曹红霞.心血管疾病的预防策略与干预模式.北京:心脏病学实践 2003,人民卫生出版社,3-10.
2 胡大一. 在循证医学原则指导下做好血脂异常的预防. 中国实用内科志, 2004(24)5:257-258.
3 Guo CS,Guo LZ. Molecular epidemiology and human genome project .Chin J Epidemiol,2000,21:405-40.郭存三,郭立征.分子流行病学与人类基因组计划.中华流行病学杂志,2000,21:405-406.
4 管思明,张银环,戚本玲,等.老年人血脂分布及其与疾病的关系.临床心血管杂志, 2000,16(4):167-168.
5 叶平主编.血脂的基础与临床.北京:人民军医出版社,2002:93.
6 Davign,Cohn JS,Mabil,et al.Apolipoprotein E and atherosclerosis:insight from animal and human studies[J].Clin Chim Acta,1999,286(l-2):115-143.
7 Linton MF , Atkinson JB , Fazio S .Prevention of atherosclerosis in apolipoprotein E deficentmiceby bone marrow transplantation[J]. Science, 1995,267:1034-1037.
8 Nikoulin IR, Curtiss LK. An apolipoproteinE synthetic peptide targets to lipoproteins in plasma and mediates both cellar lipoprotein interactions in vitro and acute clearance of choles terol-rich lipoproteins in viva[J].J Chin Invest,1998,101(1):223-234.
9 唐志红,夏敏,马静,等.载脂蛋白E基因敲除小鼠主动脉壁胆固醇含量的测定及意义.疾病控制杂志,2004,8(3):213-215.
10 覃丽,秦旭平,朱炳阳,等.Caveolirr 1 在载脂蛋白 E 基因敲除小鼠动脉粥样硬化形成中的变化.中国临床药理学与治疗学,2004,9(9):978-982.
11 Maor I,Aviram M.Oxidized low density lipoprotein leads to macrophage accumulation of unesterified cholesterol as a result of lysosomal trapping of the lipoprotein hydrolyzed cholesterylester[J].JLipid Res,1994, 35(5):803-819.
12 Lange Y,Steck TL .The role of intracellular cholesterol transport in cholesterol homeostasis[J].Trans Cell Biol,1996,6(6):205-208.
13 Mahley RW .Apoliprotein E:cholesterol transport protein with expanding role in cell biology[J].Science,1988,240(4852):622-630.
14 向伟,赵水平,马燕琳,等.冠心病患者外周血单核细胞载脂蛋白 E 基因表达的研究.中华心血管病杂志,2004,32(1):80.
15 向伟,马燕琳,符生苗,等.健康儿童载脂蛋白E基因表达的研究.中国自然医学杂志, 2004,6(4):212-215.
16 刘晓春,彭怀燕,覃桂芳,等.冠心病与 AOPE 基因多态性及其与血清 AopE 的关系.上海医学检验杂志,2003,18(1):36-39.
17 Laakso M .Insulin resistance and coronary heart dis easel J.Curr Onin Linidol,1996,7:217-226.
18 Rall.SC,KH Weisgraber,R W Mahley.Human apolipopro tein E .The complete amino acid sequence[J].Biol Chem,1982,257:4171-4178.
19 赵毅,沈霞.载脂蛋白 E 的性质、检测方法和临床意义.上海医学检验杂志. 1996,11(2):107-109.
20 吴红赤,谢汝娟,那士平,等.PCR-RFLP和PCR-SSCP检测技术在aopE基因多态性检测中的应用.肾脏病与透析肾移植杂志,1998,7(6):589-591.
21 Ordovas M. Cardiovascular disease genetics:A long and winding road. Curr Opin Lipidol,2003,4(1):47-54.
22 Marie-Luise Blue, W ishm as D L, Stanley Eucker, et al. Apolipoprotein E synthesis in human kidney,adrenal gland,and liver.Proc Natl Acad SciUSA,1983,80:283-287.
23 New man T C, Daw osn P A, Rude L L, et al. Quantitation ofapolipoprote in E m RNA in the liver and peripheral tissues of nonhuman primates.J Biol Chem,1985,260:2452-2457.
24 顾牛范,冯国称,江三多,等.中国汉族人群AOPE等位基因频率的初步研究.中华医学遗传学杂志,1996,13(1):8-12.
25 王秀花,高海青.载脂蛋白 E 多态性与冠心病患者脂代谢的临床研究.临床心血管病杂志,2000,16(10):440-442.
26 Davignon J, Gregg R E, Sing C F. LE apolipoprotein E polym orphis im and atherosclerosis. Arteroscleros is,1988,8:1-21.
27 黎旭,赵冬,刘静,等.北京自然人群载脂蛋白 E 基因多态性频率分布研究.首都医科大学学报,2003,24(3):268-270.
28 曾湘豫,秦斌,国汉帮,等.北京地区载脂蛋白 E 基因多态性和血清浓度的分布.中华神经科杂志,2000,33(4):237.
29 Dallongeville J,Cacan SL,Davignon J. Modulation of plasma triglyc-eride level by aopE phenotype analysis[J].J Lipid Res,1992,33:447-454.
30 Davignon J, Gregg RE,Sing CF.Apolipoprotein E polymorphism and atherosclerosis[J].Current Science,1993,5:19-21.
31 Sing CF, Davigon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation[J].AmJ HuGenet, 1985,37(2):268-285.
32 Utermann G, Pruin N, Steinmetz A, et al. Polymorphism of apolipoprotein E III effect of a single polym orphic gene locus on plasman lipid levels in man. Clin genet,1979,15(l):63.
33 沈丽华,柯开富,李作汉,等.载脂蛋白 E 基因多态性对血脂代谢的影响.现代神经疾病杂志,2002,2(6):345-347.
34 朱健华,潘闽,王惠民.载脂蛋白E基因多态性与健康人群血脂谱改变的关系.临床心血管病杂志,2002,18(2):63-65.
35 James M, Hagberg B, Kenneth RW,et al. AopE gene and gene-environment effects on plasma lipoprotein lipid levels[J].Physiol Genomics,2000,4:101-108.
36 Davignon J, Gregg RE,Sing CF.Apo E polymorphism and atherosclerosis. Atherosclerosis,1988,8:1.
37 Ruth FS, Borge G, Nordestgaarda CD,et al. Context-dependent and invariant associations between lipids,lipoproteins,and apolipoproteins and apolipoprotein E genotype[J].J Lipid Res,2000,41:1812-1822.
38 赵水平主编.临床血脂学[M].长沙:湖南科学技术出版社,1997,29-33.
39 Iausen IC,Gerdes LU, Sihm I,et al. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around theworld. Genet Epidenvol,1992,9:155-167.
40 Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis[J]. Current Science,1993,5:19-21.
41 Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyeeride levels by apoE phenotype: a meta-analysis. J Lipid Res,1992,33:447-454.
42 朱铁兵,王中林,赵水平,等.载脂蛋白 E 基因对血脂代谢的调节及其与冠心病的关系.[J].湖南医科大学学报,1998,23(2):149-151.
43 Boerwinkle E, Visvikis S, Welsh D, et al. The use of measured genotype in formation in the analysis of quantitative phenotypes in man. H.The role of apolipoprotein E polymorphism in deter mining levels, variability, and covariability of cholesterol, beta lipoprotein and triglycerides in a sample of unrelated individuals[J]. Am J Hum Genet 1987,27:567-582.
44 Ruth FS, Borge G, Nordestgaarda CD,et al. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype [J].J Lipid Res,2000,41:1812-1822.
45 Boerwinkle E, Visvikis S, Welsh D,et al. The use of measured genotype information in the analysis of quantitative phenotypes in man. H.The role of apolipoprotein E polymorphism in deter mining levels, variability, and covariability of cholesterol, beta lipoprotein and triglycerides in a sample of unrelated individuals[J].Am J Hum Genet 1987,27:567-582.
46 邹阳春,洪秀芳,胡大一,等.国人载脂蛋白 E 基因多态性与冠心病发病之间的相关性.中国动脉硬化杂志,2005,13(3):355-358.
47 Zannis VI,Just P W,Breslow JL .Human apolipooprotein E iso protein subclasses are genetically determined[J].Am J Hum Genet,1981,33(1):11-24.
48 Lehtimaki T, MoilanenT, Viikari J, et al. Apolipoprotein E geno types in Finnish youths: a cross-sectional and 6-year follow-up study[J].J Lipid Res,1990,31:487-495.
49 Lehtimaki T, MoilanenT, Viikari J, et al. Apolipoprotein E geno-types in Finnish youths: a cross-sectional and 6-year followupstudy[J].J Lipid Res,1990,31:487-495.
50 Srinivasan SR,Ehnhol m C,Elkasabany A,et al.In fluence of apolipoprotein E polymorphism on serum lipids and lipoprotein changes from childhood toadulthood The Bogalusa Heart Study[J].At he roscle rosis,1999,143:435-443.
51 Srinivasan SR,Ehnhol m C,Wattigney WA,et al.The relation of apoliprotein E polymorphism to multiple cardio rascular risk in children:the Bogalusa Heart Study[J]. Atherosclerosis,1996,123(1-2):33-42.
52 张晓,麦根荣,江钟炎.载脂蛋白E基因多态性对儿童血脂的影响.中国当代儿科杂志, 2001,3(1):11-13.
53 KaoJJ T, Sai KS, Chang CJ. The effects of AopE polymorphism on the distribution of lipids andlipoproteins in the Chinese population [J].Atherosclerosis, 1996,114(1):55-59.
54 Gerard Siest, Thierry Pillot, Anne Regis-Bailly, et al. Apolipoprotein E:An im portant gene and protein tofollow in laboratory medicine. Clin Chem,1995,41:1068-1086.
55 Margaret M Cobb, Howard Teitlebaum,Neil Risch, et al. Influence of dietary fat, apolipoprotien E plenotype and sex on plasm a lipoprotein levels. Circulation,1992,846:849.
56 Dallongevill J, Lussier-Cacans, Darignon J. Modulationof plasma triglyceride levels by apolipoprote in E phenotype: A meta-analysis. J Lipid Res,1992,33:447-454.
57 Reilly S, Ferrell R, Sing C.The genderspecific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester[J].Am J Hum Genet,1992,51:1311-1324.
58 Eto M, Sato T, Watanabe K, et al. Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoproteinE4[J].Athemsclerosis,1990,84:49-53.
59 张原力,游凯,张丽华,等.载脂蛋白 E 基因多态性对血脂及冠心病、动脉粥样硬化的影响.中华心血管病杂志,1998,26:443-447.
60 肖志杰,赵水平,聂赛,等.载脂蛋白E基因多态性对血脂的影响.中华流行病学杂志, 2005,26(7):533-536.
61 U term ann G, V ogelberg KH.SteinmetzA,etal. Polymorphism of apolipoprote in EⅡGenetics of hyperlipoprote in em is typeIII.Clin Genet, 1979,15(1):37-62.
62 王蓉,谢荣麟,黄文芳,等.载脂蛋白 E 基因多态性及其与Ⅳ型高脂血症的关系.四川医学,2005,26(4):400-401.
63 张雪梅,刘秉文,范萍,等.中国人内源性高甘油三酯血症载脂蛋白E基因多态性的研究.中华医学遗传学杂志,2001,18(2):100-104.
64 庞庆丰,王影.家族性高胆固醇血症患者载脂蛋白E基因多态性及其对血脂的可能影响.徐州医学院学报,2004,24(3):206-209.
65 张延红,窦相峰,尚蔚,等.家族性混合型高脂血症与载脂蛋白E基因多态性的研究高血压杂志,2004,12(2):127-130.
66 DSeDreS 1P. Diabetes 1995,42:1474.
67 de Man FH, de Beer F, van de laarse A, et al. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphateproteoglycan-bounlipoproteinlipase[J].Atherosclerosis,1998,136 (2):255-256.
68 Srinivasan SR, Ehnholm C,Elkasabany A, et al. Apolipoprotein E polymorphism Modulates the association between obesity and dys lipdemias during young adulthood: the bogalusa heart study[J].Metabolism,2001,50:696-702.
69 Miettinen TA, et al. Arterioscler Thormb 1994,11:1303.
70 Day I N , Wilson DI . Science , medicine and the future:genetics and cardiovascular risk. BMJ,2001,323:1409-1412.
71 De Man FH, de Beer, van de laarse A, Smelt AH, Leuven JA, Havekes LM Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphat proteoglycaer bound lipoprotein lipase. Atherosclerosi, 1998,136(2):255-262.
72 张莉莉,吕安林,王海昌,等.载脂蛋白 E 基因多态性与冠心病相关因素的关联性.心脏杂志,2004,16(3):252-254.
73 张雪梅,刘秉文.载脂蛋白 E 研究进展.中国动脉硬化杂志,2001,9(2):165-168.
74 Van EM, Van DKW, Herijgem M, et al. Essential role fox the(he patic) LDL receptor in macrophage apolipoprotein E-induction in serum cholesterol levels and atherosclerosis[J]Atherosclerosis,2001,164(1):103-112.
75 王克勤.脂蛋白与动脉粥样硬化[M].北京:人民卫生出版社,1995,151-160.
76 STENGARD JH , PEKKANEN J , EHNHOLM C , et al Genotypes with the apolipoprotein epsilon4 allele are pre2dictors of coronary heart disease mortality in a longitudinalstudy of elderly Finnishmen [J]. Hum Genet,1996,97:677-684.
77 张莉莉,吕安林,王海昌,等.载脂蛋白 E 基因多态性与冠心病相关因素的关联性.心脏杂志,2004,16(3):252-254.
78 彭健,彭澍,龚五星.不同血脂水平冠心病患者与载脂蛋白E基因多态性相关性分析.中华医学杂志,2000,80(7):516-517.
79 张莉,季彦.冠心病 42 例血浆载脂蛋白 E 基因型及脂类、内皮素、一氧化氮水平检测.南通医学院学报,2000,20(2):144-145.
80 朱铁兵,杨志键,马根山,等.冠心病患者载脂蛋白 E 基因多态性研究.中国循环杂志2000,15(4):221-222.
81 邹阳春,洪秀芳,胡大一,等.国人载脂蛋白 E 基因多态性与冠心病发病之间的相关性.中国动脉硬化杂志,2005,13(3):355-357.
82 欧阳涛,宋剑南,苗阳,等.冠心病痰瘀证与载脂蛋白 E 基因多态性关系的研究.中西医结合学报,2005,3(6):438-441.
83 李洁,张天民,李莎,等.冠心病家族史大学生 apoE 基因多态性的临床研究.国外医学·心血管疾病分册,2003,30:(4)248-250.
84 Ruth F S,Anne T H,Steffensen R,et al.Apolipoprotein E genotype:Epsilon
32 women are protected while epsilon 43 and epsilon 44 men are susceptible to ische mic heart disease .The Copenhagen city study.J Am Coll Cardiol,2000,35:1192-1199.
85 陈忠,黄峻,朱铁兵,等.早发冠心病患者同胞及子女血脂与载脂蛋白 E 基因多态性.临床心血管病杂志,2002,18(4):150-152.
86 Van Bockxmeer PM,M am otte CD. Apolipoprotein epsilon 4 hom ozygosity in young m en w ith coronary heart disease. Lancet,1992,340:879-880.
87 Cubrilo-Turek M,Stavljenic-Rukavina A, Sertic J, et al Apolipoprotein E genotypes and metabolic risk factors for coronary heart disease in middle-aged women. Coll Antropol,1998,22:149-155.
88 Scuteri A, Bos AJG, Zonderman AB, et al. Am J Med,2001,110(1):28-32.
89 朱铁兵,杨志键,马根山,等.冠心病患者载脂蛋白E基因多态性研究.中国循环杂志, 2000,15(4):221-222.
90 Sanghera DK, Ferrell RE, Aston CE, et al. Quantitative effects of the apolipoprotein E polymorphism in a biracial sample of 9-10-year-old girls[J].Arteriosclerosis,1996,126:35-42.
91 Nassar BA, Dunn J, Title LM, et al. Relation of genetic poly morphisms of apolipoprotein E , angiotensin converting enzyme apolipoprotein B-100,and glycoprotein IIa and early-onset coro nary artery heart disease[J]. Clin Biochem 1999,32:275-2825.
92 赵水平主编.临床血脂学.长沙:湖南科技出版社,1997,29.
93 金炜,陆元善,徐英华,等.载脂蛋白E基因多态性与急性心肌梗死及血胆固醇水平的关系.上海医学,1998,21(12)697-699.
94 Van Bockx mer F M,Cyril DS,Frances A, et al . Angiotensinrconverting enzyme and apolipoprotein E genotypes and restenosis after coronary an gioplasty. Circulation,1995,92:2066.
95 尹志农,李瑞杰,赵远华,等.冠心病患者AopE基因型与超敏CRP相关性探讨.国外医学临床生物化学与检验学分册,2004,25(5):387-389.
96 廖玫珍,姜宝法,徐传辉,等.ApoE 基因多态性与多因素作用致冠心病研究. 中国公共卫生,2004,20(1):55-56.
97 Chin B,Viira E, Tucker W,et al. Chlamydia pneumoniae,cytomegalovirus and herpes simplex virus in atherosclerosis of the carotid artery[J].Circu lation,1997,96:2144-2148.
98 陈谦,周新,刘芳,等.冠心病患者 apoE 基因调控序列-219( QT)多态性及与血脂的关系基础医学与临床,2002,22(2):121-124.
99 liveskoski E, Perola M, Lehtimaki T. Age-dependent association of Apolioprotein E genotype with coronary and aortic atheroscle rosis in middleaged men an autopsy study[J] .Circulation,1999,100:608-613.
100 白小涓,赵玫,王勃,等.心肌梗死患者及同胞血脂异常AOPE基因多态性分析.中华医学杂志,2001,81(6):340-343.
101 Chambless LE, Folsom AR, Clegg LX, et al . Carotid wall thickness is predic live of incident clinical stroke,the atherosclerosis risk in communiti(ARIC) study.Am J Epidemol,2000,161(5):478-487.
102 陈忠,黄峻,朱铁兵,等.早发冠心病患者颈总动脉内膜-中层厚度与载脂蛋白E基因型的关系.中国动脉硬化杂志,2002,10(5):434-436.
103 谢月娥,田应中,伍有权,等.不同剂量茶色素治疗高脂血症疗效比较.中国现代医学杂志,2000,10(5):81.
104 尚延忠,叶平,丁小平.载脂蛋自 E 基因多态性对调脂疗效的影响[J].中华老年心脑血管病杂志,2001,3(4):230-232.
105 Carmena R, Roederer G, Nbilloux H, LussierCacan S, Davignon J. The re sponse to lovastatin treatment in patiens with heterozygous familial hypercholester olemia is modulated apolipoproteinE polymorphism. Ivhtaboh'sm,1993,42(7):895-901.
106 张加芳,杨玖玲,张真路,等.载脂蛋白 E 基因多态性与尼尔雌醇的调脂作用.中华老年医学杂志,2002,21(5):329-312.
107 李旭平,周胜华,赵水平,等.载脂蛋白 E 的基因型对降脂治疗反应性的影响.中国现代医学杂志,2002,12(17):81-82.
108 Gerdes LU,Gerdes C,Kervinen K, et al . The apolipoprotein E ep silon 4 allele determines prognosis and the effect on prognosis of sim vastatin in survivors of myocar al infarction:a substudy of the Scandinanvian simvastatin survival study Circulation,2000,101(12) :1366-1371.
109 Takemoto M,Liao JK. Pleiotropic effect of 3-Hydroxy-3-Methylg lutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vase Bio1,2001,21:1712-1719.
110 张莉莉,吕安林,贾国良,等.载脂蛋白E基因多态性对他汀类药物调脂消斑的影响.第四军医大学学报,2004,25(11):1029-1031.
111 Allantyne CM, Herd JA, Stein EA, et al. Apolipoprotein E genotypes and response of plasma lipids and progression7regression of coronary atherosclerosis to lipid7lowering drug therapy[J]J Am Coll Cardiol,2000,36(5):1572-1578.
112 Pedro-Botet J,Schaefer EJ, Bakker Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner[J].Atherosclerosis,2001,158(1):183-193.
113 赵水平.他汀类药物降脂疗效个体差异及其机制.中南药学,2003,1(4):195-196.
114 Eto M, Sato T, Watanabe K, Iwashima Y, Nbkino I . Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with andwithout apolipoprotein E4. Atherosclerosis,1990,84(1):49-53.
115 Nettinen TA,Gylling H, Uanhanen H. Serum cholesterol response to dietary cholesterol and apoprotein E phenotype . Lancet,1988,1:1261.
116 Erkkila AT, Sarkkinen ES, Lindi V, Lehto S, Laakso M, Uusitupa MI. ApoE polymorphism and the hype rtriglyceride mic effect of dietary sucrose . Am J Cfn Nutr,2001,73(4):746-752.
117 Lehtimaki T, FmnkbergLakkala H, Solakivi T, Koivisto AM, Laippala P, Ehur hot m C, et al . The effect of shon-term fasting,apolipoproteinEgene polymor phism, and sex on plasma lipids. Am」Cfn Nutr,1997,6(3):599-605.
118 汪春红,周新,周光娣,等.冠心病易感基因载脂蛋白 E、低密度脂蛋白受体多态性与烟、酒的交互作用的研究.中华医学杂志,2004,84(7):554-558.
119 Fickl H,Van Antwerpen VL,Richards GA, et al. Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers.Athersclerosis,1996,124:75-81.
120 Smith JD, Miyata M , Poulin SE , et al. The relationship between apolipoprptein E and serum oxidation7related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res,1998,28:116-121.
121 Taimela S, Ehtimaki T, Kimmo VK. et al. The effect of physical activity on serum total and low-density lipoprotein cholesterol concentration varies with apolipoprotein E phenotype in male children and young adults. The cardiovascular Risk in Young Finns Study[J].Metabolism,1996,45(7):797-803.
1. 赵水平主编.临床血脂学.长沙:湖南科学技术出版社,1997,32.
1 叶任高主编.内科学[M].第五版.人民卫生出版社,2000,830.
2 郭宏昌,牛晓亚,张向东,等.痰浊证与血脂水平关系的研究.河南中医药学刊, 1998.13(6):18.
3 宋剑南.从生物化学角度看痰及痰瘀相关[J].中国中西医结合杂志,2000,6(3):42.
4 俞亚琴, 郭兮华. 从血流变学探讨高脂血症的痰湿改变. 辽宁中医杂志, 1995,22(6):6-7.
5 陈可冀,马晓昌.关于传统血瘀证的现代分类[J].中国中西医结合杂志, 2000,20(7):487.
6 王剑,严灿,吴丽丽,等.无形之痰实质假想.中国中医基础医学杂志, 1999,(10):44-46.
7 王东生,袁肇凯,陈方平.动脉粥样硬化与痰瘀病理.成都中医药大学学报, 2003,26(4):57-58.
8 宋剑南,刘东远,牛晓红,等.高脂血症与中医痰浊关系的实验研究.中国中医基础医学杂志,1995,1(1):49-51.
9 熊文生.从脾论治高脂血症的概况与展望.新中医,1997,(5)58-59.
10 赵建明,赵淑媛.脾虚证红细胞膜流动性改变的临床研究.中国中西医结合杂志, 1996,16(6):350-351.
11 史大卓,马晓昌,高修安.活血化瘀方药防治动脉粥样硬化概况[J].中医杂志,1995,36(1):434.
12 刘光艳,孙文静.益气活血Ⅱ号方药对家兔实验性高脂血症的影响.辽宁药物与临床, 2004,7(1):15-16.
13 王亚红,姜洪茹,郭维琴,等.降脂通脉方抗动脉粥样硬化临床研究.北京中医药大学学报,2000,23(3):52-54.
14 杨惠民,盛彤,韩丽蓓,等.调脂通脉颗粒治疗老年高脂血症痰瘀证的临床研究.中华中医药杂志(原中国医药学报),2005,20(4):247-248.
15 雷载权主编.中药学.上海:上海科学技术出版社,1995,154.
16 刘雪利.陈皮果胶对家兔实验性动脉周样硬化的形态学影响.现代应用药学, 1992,9(3):106.
17 陈丽娜, 朱晓新. 丹参改善血液流变性的实验研究进展.中国中药杂志,2005,30(8):630-635.
18 严常开,刘惟莞,敖英,等.丹参素胶囊活血化瘀作用的实验研究.中成药, 2003,25(8):637.
19 水蛭泻浊汤治疗高脂血症 48 例临床观察[J].吉林中医药,2002,(4):12.
20 秦百宜,许素贞,钱彦丛,等.水蛭对血清胆固醇、血液粘度及血栓形成的影响.中药材,1994,17(10):33-35.
21 陶晋舆,吕环,张秋菊,等.泽泻抗动脉粥样硬化作用系列研究(二)[J].北京中医学院学报,1991,14(6):51.
22 李续娥,杨水云,赵文明,等.决明子蛋白质和蒽醌苷对高脂血症大鼠血液流变学的影响.中草药,2002,33(5):429-431.
23 毛峻琴,宓鹤鸣.大豆异黄酮的研究进展.中草药,2000,31(1):61-64.
24 胡大一.在循证医学原则指导下做好血脂异常的预防.中国实用内科杂志,2004(24)5:257-258
25 徐成斌.血脂异常的药物治疗新进展.中华心血管病杂志,2001,29:189-192.
26 马丽媛,傅继第.载脂蛋白 B 基因多态性分析及其临床意义[J].高血压杂志, 1999,7(3):201.
27 Mackness ML,Durrington PN,Mackness B .How high-de nsity lipoproteins against the effects oflipidperoxidation.CurrOpin Lipidol ,2000,11:383-388.
28 李友元.自由基反应与肝损伤[J].国外医学·生理病理科学与临床分册, 1991,11(3):13
29 黄春林.降脂中药的探索.广东医学,1984,(50):21.
30 孙锡铭,蔡江海,王南,等.用两性霉素 B-细胞模型法筛选胆固醇内源性合成抑制剂.中西医结合杂志,1989,9(10):604.
31 周文泉,方醉,周鸿.高脂血症中西医结合研究进展.中医杂志,1992,33(8):52.
32 刘春堂,胡文豪.痰瘀同治降血脂 36 例.四川中医,1986,4(9):43.
33 刘君莉.水蛭粉治疗高脂血症 25 例.新中医,1985,17(2):36.
34 屈柏松,李家庚.实用中医心血管病学.第 1 版,北京:科学技术文献出版社, 1993,294-300.
35 赵春亭,赵子文主编.临床血液流变学.第 1 版.北京:人民卫生出版社,1997.
36 王敏,王灵,赵蜀琼.老年高脂血症患者血液流变学指标的改变.中国血液流变学杂志,2000,10(3):157.
37 刘晓颖,李凤文,张立石,等.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响[J].中国中医基础医学杂志,1998,4(3):15-17.
38 Gotto AM,Whitney E,Stein EA, et al. Relation between base line and on treatment lipid parameters and first acute major coro nary events in the air force/texas coronary atherosclerosis preven tion study Circulation,2000,101:477-484.
39 Manninen V, Tenkanen L,Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study implications for treatment. Circulation,1992,85:37-45.
40 Assmann G. Lipid Metabolism Disorders and.CHD MMV Medizin Verlag,1993,16:41-43.
41 Ass mann G,Cullen P,Schulte H. The Munster heart study (PROCAM) resultsof follow-up at 8 years. Eur Heart J,1998,19(suppl):A2-A11.
42 de Andrade M, Thandi I,Brown S,et al . Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis[J].Am J Hum Genet,1995,56:379-390.
43 Evans AE. Hum Genet, 1993,92(2):101-107.
44 王晔,郑惠民.载脂蛋白 E 与脑血管病.国外医学脑血管疾病分册,2000,8:139-141.
45 Zaman MM, Ikemoto S, Yoshiike N, et al. Association of apolipopro tein genetic polymorphism with plasma cholesterol in a Japanese ru ral population: the Shibata Study. Arterioscler Thromb Vasc Biol,1997,17:3495-350.
46 Pablos-mendez A, Mayeux R, Ngai C, et al. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioseler Thromb Vase Biol,1997,17:3534-3541.
47 Hixson JE. Arteriosder Tluomb Vase Biol,1991,11(5):1237-1244.
48 李伟,管思明,戚本玲,等.老年冠心病患者载脂蛋白 E 基因多态性检测的临床意义.中华老年医学杂志.2003,22(9):214-217.
49 周娟,朱健华,沈丽华等.冠心病及脑梗塞患者载脂蛋白E基因多态性研究.中国误诊学杂志,2004,4(1):19-21.
50 张原力,游凯,张丽华,等.载脂蛋白 E 基因多态性对血脂及冠心病、动脉粥样硬化的影响.中华心血管病杂志,1998,26:443-447.
51 王秀花,高海青.载脂蛋白 E 多态性与冠心病患者脂代谢的临床研究.临床心血管病杂志,2000,16(10):440-442.
52 刘华欣,曹丽春,周涌,等.不同人群载脂蛋白 E 基因多态性分布状态的研究.中国医师杂志,2000,2(9):530-532.
53 Sing CF, Davigon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation [J].Am J Hum Genet, 1985,37(2):268-285.
54 Lin SK, Kao JT, Tsai SM, Tsai LY, Lin Mr,Lai CJ, et al. Association of apolipoprotein E genotypes with serum lipid profiles in a healthy population of Tai wan. Ann Qin Lab Sci,2004,34(4):443-448.
55 Loparev V N,Cartas M A,Monken C E,et al.An effi cient and simple method of DNA extraction from whole blood and cell line to identify infection agents .J VirolMethods,1990,34(1):105-109.
56 Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis[J]. Current Science,1993,5:11-21.
57 de Andrade M, Thandi I,Brown S,et al . Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis[J].Am J Hum Genet,1995,56:379-390.
58 袁如玉,梁爽霖,毛用敏,等.载脂蛋白E等位基因多态性与冠心病相关性的研究[J].中国心血管病杂志,1998,3:320-322.
59 Pablos-mendez A, Mayeux R, Ngai C, et al. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly pop elation. Arterioseler Thromb Vase Biol, 1997,17:3534-3541.
60 Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyeeride levels by apoE phenotype:a meta-analysis. J Lipid Res,1992,33:447-454.
61 Zhao SP et al.Arteioscler Thromb,1993,13:316-323.
62 Eggertesen G,Tegel man K,Ericsson S,et al. Apolipoprotein polymorphism in a healthy Swedish popula-tion:Variation of allele frequency with age and relation to serum lipid concentration .Clin Chem1993,39:2525-2525.
63 Pablos Mendez A,Richard M,Colleen N,et al.Associa tion of apoE polymorphism with plasma lipid levels in a multiethinic elderly population .Arterioscler Thromb Vase Bi of 1997,17:3534-3541.
64 Naoumova RP, Marais AD, Mountney J, et al. Plasma meva Ionic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMGCoA reductase inhibitorsinfamilialbypercholesterolaem[J].Atheroscleroszs,1996,119(2):
203.
65 Wilson PW, Schaefer EJ, Larson MG, et al. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioseler Tbromb Vase Biol, 1996,16:1250-1255.
66 Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet, 1985, 37:268-285.
67 袁肇凯,简亚平,黄献平,等.高脂血症痰瘀辨证的血脂和血流动力学检测分析.湖南中医学院学报,2001,21(3):1-4.
68 李旭平,周胜华,赵水平,等.载脂蛋白 E 的基因型对降脂治疗反应性的影响.中国现代医学杂志,2002,12(17):81-82.
69 Carmena R, Roederer G, Nbilloux H, LussierCacan S, Davignon J. The response to lovastatin treatment in patiens with heterozygous familial hypercholesterolemia is modulated by apolipoproteinE polymorphism. Metabolism, 1993,42(7):895-901.
70 O' Nblley JP, Illingworth DR. The affluence of apo;ipoproteinE phenotype on the response to lovastatin therapy in patients with heteroaygous familial 场 perchol esterolemia. AItaboh'sm, 1990,39(2):150-154.
71 Sandllehy C, Casals E, Rodriguez cellar C, Zambon D,qnet J, Ballesta AM, et al . Lack of interaction of apolipoproteinE phenotype with the lipoproteinrespouse to lovastatin or gemfibrozil in patients with primary 场percholesterole mia Ivktabolism, 1998,47(5):560-565.